| Year |
Citation |
Score |
| 2023 |
Rissman RA, Langford O, Raman R, Donohue MC, Abdel-Latif S, Meyer MR, Wente-Roth T, Kirmess KM, Ngolab J, Winston CN, Jimenez-Maggiora G, Rafii MS, Sachdev P, West T, Yarasheski KE, ... ... Aisen PS, et al. Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37932961 DOI: 10.1002/alz.13542 |
0.788 |
|
| 2023 |
Touroutoglou A, Katsumi Y, Brickhouse M, Zaitsev A, Eckbo R, Aisen P, Beckett L, Dage JL, Eloyan A, Foroud T, Ghetti B, Griffin P, Hammers D, Jack CR, Kramer JH, et al. The Sporadic Early-onset Alzheimer's Disease Signature Of Atrophy: Preliminary Findings From The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) Cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37850549 DOI: 10.1002/alz.13466 |
0.371 |
|
| 2023 |
Grill JD, Flournoy C, Dhadda S, Ernstrom K, Sperling R, Henry DM, Tranotti K, Harris R, Kanekiyo M, Gee M, Irizarry M, Kramer L, Aisen P, Raman R. Eligibility rates among racially and ethnically diverse US participants in Phase 2 and Phase 3 placebo-controlled, double-blind, randomized trials of lecanemab and elenbecestat in early Alzheimer's disease. Annals of Neurology. PMID 37830926 DOI: 10.1002/ana.26819 |
0.561 |
|
| 2023 |
Nudelman KNH, Jackson T, Rumbaugh M, Eloyan A, Abreu M, Dage JL, Snoddy C, Faber KM, Foroud T, Hammers DB, Taurone A, Thangarajah M, Aisen P, Beckett L, Kramer J, et al. Pathogenic variants in the Longitudinal Early-onset Alzheimer's Disease Study cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37801072 DOI: 10.1002/alz.13482 |
0.378 |
|
| 2023 |
Veitch DP, Weiner MW, Miller M, Aisen PS, Ashford MA, Beckett LA, Green RC, Harvey D, Jack CR, Jagust W, Landau SM, Morris JC, Nho KT, Nosheny R, Okonkwo O, et al. The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37698424 DOI: 10.1002/alz.13449 |
0.471 |
|
| 2023 |
Cho H, Mundada NS, Apostolova LG, Carrillo MC, Shankar R, Amuiri AN, Zeltzer E, Windon CC, Soleimani-Meigooni DN, Tanner JA, Heath CL, Lesman-Segev OH, Aisen P, Eloyan A, Lee HS, et al. Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37690109 DOI: 10.1002/alz.13453 |
0.419 |
|
| 2023 |
Nemes S, Logan PE, Manchella MK, Mundada NS, La Joie R, Polsinelli AJ, Hammers DB, Koeppe RA, Foroud TM, Nudelman KN, Eloyan A, Iaccarino L, Dorsant-Ardón V, Taurone A, Thangarajah M, ... ... Aisen P, et al. Sex and APOE ε4 carrier effects on atrophy, amyloid PET, and tau PET burden in early-onset Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37496307 DOI: 10.1002/alz.13403 |
0.394 |
|
| 2023 |
Dage JL, Eloyan A, Thangarajah M, Hammers DB, Fagan AM, Gray JD, Schindler SE, Snoddy C, Nudelman KNH, Faber KM, Foroud T, Aisen P, Griffin P, Grinberg LT, Iaccarino L, et al. Cerebrospinal fluid biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37491668 DOI: 10.1002/alz.13399 |
0.389 |
|
| 2023 |
Eloyan A, Thangarajah M, An N, Borowski BJ, Reddy AL, Aisen P, Dage JL, Foroud T, Ghetti B, Griffin P, Hammers D, Iaccarino L, Jack CR, Kirby K, Kramer J, et al. White matter hyperintensities are higher among early-onset Alzheimer's disease participants than their cognitively normal and early-onset nonAD peers: Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37491599 DOI: 10.1002/alz.13402 |
0.411 |
|
| 2023 |
Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS. Trial of Solanezumab in Preclinical Alzheimer's Disease. The New England Journal of Medicine. PMID 37458272 DOI: 10.1056/NEJMoa2305032 |
0.751 |
|
| 2023 |
Polsinelli AJ, Wonderlin RJ, Hammers DB, Garcia AP, Eloyan A, Taurone A, Thangarajah M, Beckett L, Gao S, Wang S, Kirby K, Logan PE, Aisen P, Dage JL, Foroud T, et al. Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37296082 DOI: 10.1002/alz.13344 |
0.326 |
|
| 2023 |
Hammers DB, Eloyan A, Taurone A, Thangarajah M, Beckett L, Gao S, Kirby K, Aisen P, Dage JL, Foroud T, Griffin P, Grinberg LT, Jack CR, Kramer J, Koeppe R, et al. Profiling baseline performance on the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort near the midpoint of data collection. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 37256497 DOI: 10.1002/alz.13160 |
0.418 |
|
| 2023 |
Rafii MS, Aisen PS. Detection and treatment of Alzheimer's disease in its preclinical stage. Nature Aging. 3: 520-531. PMID 37202518 DOI: 10.1038/s43587-023-00410-4 |
0.729 |
|
| 2023 |
Kirn DR, Grill JD, Aisen P, Ernstrom K, Gale S, Heidebrink J, Jicha G, Jimenez-Maggiora G, Johnson L, Peskind E, McCann K, Shaffer E, Sultzer D, Wang S, Sperling R, et al. Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment. Alzheimer's Research & Therapy. 15: 88. PMID 37131229 DOI: 10.1186/s13195-023-01235-4 |
0.4 |
|
| 2023 |
Baldaranov D, Garcia V, Miller G, Donohue MC, Shaw LM, Weiner M, Petersen RC, Aisen P, Raman R, Rafii MS. Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease. Alzheimer's & Dementia (Amsterdam, Netherlands). 15: e12431. PMID 37091309 DOI: 10.1002/dad2.12431 |
0.687 |
|
| 2023 |
Hampel H, Hu Y, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, et al. The amyloid-β pathway in Alzheimer's disease: a plain language summary. Neurodegenerative Disease Management. PMID 36994753 DOI: 10.2217/nmt-2022-0037 |
0.357 |
|
| 2023 |
Nho K, Risacher SL, Apostolova L, Bice PJ, Brosch J, Deardorff R, Faber K, Farlow MR, Foroud T, Gao S, Rosewood T, Kim JP, Nudelman K, Yu M, Aisen P, et al. Novel Alzheimer's disease locus identified by genome-wide association analysis of cerebral tau deposition on PET. Medrxiv : the Preprint Server For Health Sciences. PMID 36993271 DOI: 10.1101/2023.02.27.23286048 |
0.509 |
|
| 2023 |
Petersen RC, Aisen PS, Andrews JS, Atri A, Matthews BR, Rentz DM, Siemers ER, Weber CJ, Carrillo MC. Expectations and clinical meaningfulness of randomized controlled trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 36748826 DOI: 10.1002/alz.12959 |
0.42 |
|
| 2023 |
Winston CN, Langford O, Levin N, Raman R, Yarasheski K, West T, Abdel-Latif S, Donohue M, Nakamura A, Toba K, Masters CL, Doecke J, Sperling RA, Aisen PS, Rissman RA. Evaluation of Blood-Based Plasma Biomarkers as Potential Markers of Amyloid Burden in Preclinical Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. PMID 36710683 DOI: 10.3233/JAD-221118 |
0.671 |
|
| 2022 |
Hampel H, Au R, Mattke S, van der Flier WM, Aisen P, Apostolova L, Chen C, Cho M, De Santi S, Gao P, Iwata A, Kurzman R, Saykin AJ, Teipel S, Vellas B, et al. Designing the next-generation clinical care pathway for Alzheimer's disease. Nature Aging. 2: 692-703. PMID 37118137 DOI: 10.1038/s43587-022-00269-x |
0.327 |
|
| 2022 |
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, et al. Lecanemab in Early Alzheimer's Disease. The New England Journal of Medicine. PMID 36449413 DOI: 10.1056/NEJMoa2212948 |
0.4 |
|
| 2022 |
Mindt MR, Okonkwo O, Weiner MW, Veitch DP, Aisen P, Ashford M, Coker G, Donohue MC, Langa KM, Miller G, Petersen R, Raman R, Nosheny R. Improving generalizability and study design of Alzheimer's disease cohort studies in the United States by including under-represented populations. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 36372959 DOI: 10.1002/alz.12823 |
0.372 |
|
| 2022 |
Weiner MW, Veitch DP, Miller MJ, Aisen PS, Albala B, Beckett LA, Green RC, Harvey D, Jack CR, Jagust W, Landau SM, Morris JC, Nosheny R, Okonkwo OC, Perrin RJ, et al. Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 36209495 DOI: 10.1002/alz.12797 |
0.437 |
|
| 2022 |
Rafii MS, Sperling RA, Donohue MC, Zhou J, Roberts C, Irizarry MC, Dhadda S, Sethuraman G, Kramer LD, Swanson CJ, Li D, Krause S, Rissman RA, Walter S, Raman R, ... ... Aisen PS, et al. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35971310 DOI: 10.1002/alz.12748 |
0.812 |
|
| 2022 |
Insel PS, Young CB, Aisen PS, Johnson KA, Sperling RA, Mormino EC, Donohue MC. Tau positron emission tomography in preclinical Alzheimer's disease. Brain : a Journal of Neurology. PMID 35962782 DOI: 10.1093/brain/awac299 |
0.516 |
|
| 2022 |
Langbaum JB, Zissimopoulos J, Au R, Bose N, Edgar CJ, Ehrenberg E, Fillit H, Hill CV, Hughes L, Irizarry M, Kremen S, Lakdawalla D, Lynn N, Malzbender K, Maruyama T, ... ... Aisen PS, et al. Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35946590 DOI: 10.1002/alz.12737 |
0.411 |
|
| 2022 |
Hampel H, Elhage A, Shaw LM, Aisen P, Chen C, Lleó A, Iwatsubo T, Iwata A, Yamada M, Ikeuchi T, Jia J, Wang H, Teunissen CE, Peskind E, Blennow K, et al. The use of lumbar puncture and safety recommendations in Alzheimer's disease: a plain language summary. Neurodegenerative Disease Management. PMID 35866715 DOI: 10.2217/nmt-2022-0012 |
0.3 |
|
| 2022 |
Morris JC, Weiner M, Xiong C, Beckett L, Coble D, Saito N, Aisen PS, Allegri R, Benzinger TLS, Berman SB, Cairns NJ, Carrillo MC, Chui HC, Chhatwal JP, Cruchaga C, et al. Autosomal dominant and sporadic late onset Alzheimer disease share a common in vivo pathophysiology. Brain : a Journal of Neurology. PMID 35580594 DOI: 10.1093/brain/awac181 |
0.46 |
|
| 2022 |
Assunção SS, Sperling RA, Ritchie C, Kerwin DR, Aisen PS, Lansdall C, Atri A, Cummings J. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease. Alzheimer's Research & Therapy. 14: 54. PMID 35440022 DOI: 10.1186/s13195-022-00984-y |
0.59 |
|
| 2022 |
Aisen PS, Jimenez-Maggiora GA, Rafii MS, Walter S, Raman R. Early-stage Alzheimer disease: getting trial-ready. Nature Reviews. Neurology. PMID 35379951 DOI: 10.1038/s41582-022-00645-6 |
0.718 |
|
| 2022 |
Jimenez-Maggiora GA, Bruschi S, Qiu H, So JS, Aisen PS. Corrigendum to: ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer's disease and Alzheimer's disease-related dementias clinical trials. Jamia Open. 5: ooac008. PMID 35224459 DOI: 10.1093/jamiaopen/ooac008 |
0.45 |
|
| 2022 |
Ashford MT, Raman R, Miller G, Donohue MC, Okonkwo OC, Mindt MR, Nosheny RL, Coker GA, Petersen RC, Aisen PS, Weiner MW. Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 35213778 DOI: 10.1002/alz.12640 |
0.333 |
|
| 2022 |
Grober E, Lipton RB, Sperling RA, Papp KV, Johnson KA, Rentz DM, Veroff AE, Aisen PS, Ezzati A. Associations of Stages of Objective Memory Impairment (SOMI) with Amyloid PET and Structural MRI: The A4 Study. Neurology. PMID 35197359 DOI: 10.1212/WNL.0000000000200046 |
0.344 |
|
| 2022 |
Jimenez-Maggiora GA, Bruschi S, Qiu H, So JS, Aisen PS. ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer's disease and Alzheimer's disease-related dementias clinical trails. Jamia Open. 5: ooab119. PMID 35156002 DOI: 10.1093/jamiaopen/ooab119 |
0.442 |
|
| 2022 |
Petersen KK, Grober E, Lipton RB, Sperling RA, Buckley RF, Aisen PS, Ezzati A. Impact of sex and ε4 on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults. Alzheimer's & Dementia (Amsterdam, Netherlands). 14: e12271. PMID 35155730 DOI: 10.1002/dad2.12271 |
0.515 |
|
| 2022 |
Kellar D, Register T, Lockhart SN, Aisen P, Raman R, Rissman RA, Brewer J, Craft S. Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial. Scientific Reports. 12: 1346. PMID 35079029 DOI: 10.1038/s41598-022-05165-3 |
0.63 |
|
| 2021 |
Spira AP, Zipunnikov V, Raman R, Choi J, Di J, Bai J, Carlsson CM, Mintzer JE, Marshall GA, Porsteinsson AP, Yaari R, Wanigatunga SK, Kim J, Wu MN, Aisen PS, et al. Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies. Sleep Advances : a Journal of the Sleep Research Society. 2: zpab015. PMID 34661109 DOI: 10.1093/sleepadvances/zpab015 |
0.521 |
|
| 2021 |
Tosun D, Demir Z, Veitch DP, Weintraub D, Aisen P, Jack CR, Jagust WJ, Petersen RC, Saykin AJ, Shaw LM, Trojanowski JQ, Weiner MW. Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34647694 DOI: 10.1002/alz.12480 |
0.461 |
|
| 2021 |
Kaye J, Aisen P, Amariglio R, Au R, Ballard C, Carrillo M, Fillit H, Iwatsubo T, Jimenez-Maggiora G, Lovestone S, Natanegara F, Papp K, Soto ME, Weiner M, Vellas B. Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force. The Journal of Prevention of Alzheimer's Disease. 8: 513-519. PMID 34585227 DOI: 10.14283/jpad.2021.36 |
0.366 |
|
| 2021 |
Veitch DP, Weiner MW, Aisen PS, Beckett LA, DeCarli C, Green RC, Harvey D, Jack CR, Jagust W, Landau SM, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Rivera-Mindt M, et al. Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34581485 DOI: 10.1002/alz.12422 |
0.435 |
|
| 2021 |
McDade E, Voytyuk I, Aisen P, Bateman RJ, Carrillo MC, De Strooper B, Haass C, Reiman EM, Sperling R, Tariot PN, Yan R, Masters CL, Vassar R, Lichtenthaler SF. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature Reviews. Neurology. PMID 34548654 DOI: 10.1038/s41582-021-00545-1 |
0.562 |
|
| 2021 |
Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. The Amyloid-β Pathway in Alzheimer's Disease. Molecular Psychiatry. PMID 34456336 DOI: 10.1038/s41380-021-01249-0 |
0.389 |
|
| 2021 |
Ngolab J, Donohue M, Belsha A, Salazar J, Cohen P, Jaiswal S, Tan V, Gessert D, Korouri S, Aggarwal NT, Alber J, Johnson K, Jicha G, van Dyck C, Lah J, ... ... Aisen PS, et al. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. Alzheimer's & Dementia (Amsterdam, Netherlands). 13: e12199. PMID 34430703 DOI: 10.1002/dad2.12199 |
0.8 |
|
| 2021 |
Edgar CJ, Siemers E, Maruff P, Petersen RC, Aisen PS, Weiner MW, Albala B. Pilot Evaluation of the Unsupervised, At-Home Cogstate Brief Battery in ADNI-2. Journal of Alzheimer's Disease : Jad. PMID 34366337 DOI: 10.3233/JAD-210201 |
0.432 |
|
| 2021 |
Raman R, Quiroz YT, Langford O, Choi J, Ritchie M, Baumgartner M, Rentz D, Aggarwal NT, Aisen P, Sperling R, Grill JD. Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial. Jama Network Open. 4: e2114364. PMID 34228129 DOI: 10.1001/jamanetworkopen.2021.14364 |
0.571 |
|
| 2021 |
Salloway S, Farlow M, McDade E, Clifford DB, Wang G, Llibre-Guerra JJ, Hitchcock JM, Mills SL, Santacruz AM, Aschenbrenner AJ, Hassenstab J, Benzinger TLS, Gordon BA, Fagan AM, Coalier KA, ... ... Aisen PS, et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. Nature Medicine. PMID 34155411 DOI: 10.1038/s41591-021-01369-8 |
0.404 |
|
| 2021 |
Aisen PS, Bateman RJ, Carrillo M, Doody R, Johnson K, Sims JR, Sperling R, Vellas B. Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force. The Journal of Prevention of Alzheimer's Disease. 8: 306-312. PMID 34101788 DOI: 10.14283/jpad.2021.21 |
0.373 |
|
| 2021 |
Berkness T, Carrillo MC, Sperling R, Petersen R, Aisen P, Flournoy C, Snyder H, Raman R, Grill JD. The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program. The Journal of Prevention of Alzheimer's Disease. 8: 286-291. PMID 34101785 DOI: 10.14283/jpad.2021.12 |
0.357 |
|
| 2021 |
Kellar D, Lockhart SN, Aisen P, Raman R, Rissman RA, Brewer J, Craft S. Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease. The Journal of Prevention of Alzheimer's Disease. 8: 240-248. PMID 34101779 DOI: 10.14283/jpad.2021.14 |
0.359 |
|
| 2021 |
Vellas B, Aisen P. New Hope for Alzheimer's Disease. The Journal of Prevention of Alzheimer's Disease. 8: 238-239. PMID 34101778 DOI: 10.14283/jpad.2021.26 |
0.389 |
|
| 2021 |
Hampel H, Shaw LM, Aisen P, Chen C, Lleó A, Iwatsubo T, Iwata A, Yamada M, Ikeuchi T, Jia J, Wang H, Teunissen CE, Peskind E, Blennow K, Cummings J, et al. State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34043269 DOI: 10.1002/alz.12372 |
0.367 |
|
| 2021 |
Apostolova LG, Aisen P, Eloyan A, Fagan A, Fargo KN, Foroud T, Gatsonis C, Grinberg LT, Jack CR, Kramer J, Koeppe R, Kukull WA, Murray ME, Nudelman K, Rumbaugh M, et al. The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 34018654 DOI: 10.1002/alz.12350 |
0.435 |
|
| 2021 |
Sato K, Ihara R, Suzuki K, Niimi Y, Toda T, Jimenez-Maggiora G, Langford O, Donohue MC, Raman R, Aisen PS, Sperling RA, Iwata A, Iwatsubo T. Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial-Ready Cohort study. Alzheimer's & Dementia (New York, N. Y.). 7: e12135. PMID 33778148 DOI: 10.1002/trc2.12135 |
0.54 |
|
| 2021 |
Sperling R, Henley D, Aisen PS, Raman R, Donohue MC, Ernstrom K, Rafii MS, Streffer J, Shi Y, Karcher K, Raghavan N, Tymofyeyev Y, Bogert J, Brashear HR, Novak G, et al. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial. Jama Neurology. PMID 33464300 DOI: 10.1001/jamaneurol.2020.4857 |
0.735 |
|
| 2021 |
Papp KV, Rentz DM, Maruff P, Sun CK, Raman R, Donohue MC, Schembri A, Stark C, Yassa MA, Wessels AM, Yaari R, Holdridge KC, Aisen PS, Sperling RA. The Computerized Cognitive Composite (C3) in an Alzheimer's Disease Secondary Prevention Trial. The Journal of Prevention of Alzheimer's Disease. 8: 59-67. PMID 33336226 DOI: 10.14283/jpad.2020.38 |
0.466 |
|
| 2020 |
Galvin JE, Aisen P, Langbaum JB, Rodriguez E, Sabbagh M, Stefanacci R, Stern RA, Vassey EA, de Wilde A, West N, Rubino I. Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management. Frontiers in Neurology. 11: 592302. PMID 33551954 DOI: 10.3389/fneur.2020.592302 |
0.354 |
|
| 2020 |
Sur C, Kost J, Scott D, Adamczuk K, Fox NC, Cummings JL, Tariot PN, Aisen PS, Vellas B, Voss T, Mahoney E, Mukai Y, Kennedy ME, Lines C, Michelson D, et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. Brain : a Journal of Neurology. PMID 33253354 DOI: 10.1093/brain/awaa332 |
0.32 |
|
| 2020 |
Marshall GA, Sikkes SAM, Amariglio RE, Gatchel JR, Rentz DM, Johnson KA, Langford O, Sun CK, Donohue MC, Raman R, Aisen PS, Sperling RA, Galasko DR. Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study. Alzheimer's & Dementia (Amsterdam, Netherlands). 12: e12118. PMID 33163609 DOI: 10.1002/dad2.12118 |
0.417 |
|
| 2020 |
Wessels AM, Lines C, Stern RA, Kost J, Voss T, Mozley LH, Furtek C, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, Dupre N, Randolph C, Michelson D, et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 33049114 DOI: 10.1002/alz.12164 |
0.401 |
|
| 2020 |
Mackin RS, Insel PS, Landau S, Bickford D, Morin R, Rhodes E, Tosun D, Rosen HJ, Butters M, Aisen P, Raman R, Saykin A, Toga A, Jack C, Koeppe R, et al. Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden: Findings From the Alzheimer's Disease Neuroimaging Initiative Depression Project. Biological Psychiatry. PMID 32980132 DOI: 10.1016/J.Biopsych.2020.06.017 |
0.356 |
|
| 2020 |
Rafii MS, Aisen PS. The search for Alzheimer disease therapeutics - same targets, better trials? Nature Reviews. Neurology. PMID 32963375 DOI: 10.1038/s41582-020-00414-3 |
0.674 |
|
| 2020 |
Aisen PS, Raman R. Authors response to D Umbricht, letter to the editor referring Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky Business. The Journal of Prevention of Alzheimer's Disease, 2020. The Journal of Prevention of Alzheimer's Disease. 7: 300. PMID 32920636 DOI: 10.14283/jpad.2020.33 |
0.454 |
|
| 2020 |
Walter S, Langford OG, Clanton TB, Jimenez-Maggiora GA, Raman R, Rafii MS, Shaffer EJ, Sperling RA, Cummings JL, Aisen PS. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years. The Journal of Prevention of Alzheimer's Disease. 7: 234-241. PMID 32920625 DOI: 10.14283/jpad.2020.47 |
0.767 |
|
| 2020 |
Jimenez-Maggiora GA, Bruschi S, Raman R, Langford O, Donohue M, Rafii MS, Sperling RA, Cummings JL, Aisen PS. TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology. The Journal of Prevention of Alzheimer's Disease. 7: 226-233. PMID 32920624 DOI: 10.14283/jpad.2020.48 |
0.729 |
|
| 2020 |
Walter S, Clanton TB, Langford OG, Rafii MS, Shaffer EJ, Grill JD, Jimenez-Maggiora GA, Sperling RA, Cummings JL, Aisen PS. Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD). The Journal of Prevention of Alzheimer's Disease. 7: 219-225. PMID 32920623 DOI: 10.14283/jpad.2020.46 |
0.759 |
|
| 2020 |
Langford O, Raman R, Sperling RA, Cummings J, Sun CK, Jimenez-Maggiora G, Aisen PS, Donohue MC. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials. The Journal of Prevention of Alzheimer's Disease. 7: 213-218. PMID 32920622 DOI: 10.14283/jpad.2020.44 |
0.585 |
|
| 2020 |
Aisen PS, Sperling RA, Cummings J, Donohue MC, Langford O, Jimenez-Maggiora GA, Rissman RA, Rafii MS, Walter S, Clanton T, Raman R. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease (TRC-PAD) Project: An Overview. The Journal of Prevention of Alzheimer's Disease. 7: 208-212. PMID 32920621 DOI: 10.14283/jpad.2020.45 |
0.58 |
|
| 2020 |
Grill JD, Raman R, Ernstrom K, Sultzer DL, Burns JM, Donohue MC, Johnson KA, Aisen PS, Sperling RA, Karlawish J. Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment. Jama Neurology. PMID 32777010 DOI: 10.1001/Jamaneurol.2020.2734 |
0.624 |
|
| 2020 |
Yu JT, Xu W, Tan CC, Andrieu S, Suckling J, Evangelou E, Pan A, Zhang C, Jia J, Feng L, Kua EH, Wang YJ, Wang HF, Tan MS, Li JQ, ... ... Aisen PS, et al. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 32690803 DOI: 10.1136/Jnnp-2019-321913 |
0.492 |
|
| 2020 |
Dyer AH, Murphy C, Briggs R, Lawlor B, Kennelly SP, Lawlor B, Segurado R, Kennelly S, Marcel GM, Howard R, Pasquier F, Borjesson-Hanson A, Tsolaki M, Lucca U, ... ... Aisen P, et al. Antidepressant Use and Orthostatic Hypotension in Older Adults Living with Mild-to-Moderate Alzheimer Disease. International Journal of Geriatric Psychiatry. PMID 32668020 DOI: 10.1002/gps.5377 |
0.37 |
|
| 2020 |
Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, Donohue MC, Brewer JB, Jenkins C, Harless K, Gessert D, Aisen PS. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. Jama Neurology. PMID 32568367 DOI: 10.1001/Jamaneurol.2020.1840 |
0.78 |
|
| 2020 |
Raghavan NS, Dumitrescu L, Mormino E, Mahoney ER, Lee AJ, Gao Y, Bilgel M, Goldstein D, Harrison T, Engelman CD, Saykin AJ, Whelan CD, Liu JZ, Jagust W, Albert M, ... ... Aisen P, et al. Association Between Common Variants in RBFOX1, an RNA-Binding Protein, and Brain Amyloidosis in Early and Preclinical Alzheimer Disease. Jama Neurology. PMID 32568366 DOI: 10.1001/Jamaneurol.2020.1760 |
0.561 |
|
| 2020 |
Aisen PS, Raman R. Viewpoint: Futility Analyses in Alzheimer's Disease (AD) Clinical Trials: A Risky Business. The Journal of Prevention of Alzheimer's Disease. 7: 195-196. PMID 32463073 DOI: 10.14283/jpad.2020.20 |
0.46 |
|
| 2020 |
Aisen PS, Cummings J, Doody R, Kramer L, Salloway S, Selkoe DJ, Sims J, Sperling RA, Vellas B. The Future of Anti-Amyloid Trials. The Journal of Prevention of Alzheimer's Disease. 7: 146-151. PMID 32463066 DOI: 10.14283/jpad.2020.24 |
0.559 |
|
| 2020 |
Gauthier S, Aisen PS, Cummings J, Detke MJ, Longo FM, Raman R, Sabbagh M, Schneider L, Tanzi R, Tariot P, Weiner M, Touchon J, Vellas B. Non-Amyloid Approaches to Disease Modification for Alzheimer's Disease: An EU/US CTAD Task Force Report. The Journal of Prevention of Alzheimer's Disease. 1-6. PMID 32420298 DOI: 10.14283/jpad.2020.18 |
0.33 |
|
| 2020 |
Donohue MC, Model F, Delmar P, Volye N, Liu-Seifert H, Rafii MS, Aisen PS. Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32270600 DOI: 10.1002/Alz.12058 |
0.691 |
|
| 2020 |
Sperling RA, Donohue MC, Raman R, Sun CK, Yaari R, Holdridge K, Siemers E, Johnson KA, Aisen PS. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. Jama Neurology. PMID 32250387 DOI: 10.1001/Jamaneurol.2020.0387 |
0.578 |
|
| 2020 |
Barger C, Fockler J, Kwang W, Moore S, Flenniken D, Ulbricht A, Aisen P, Weiner MW. Data-Driven Participant Recruitment: Findings from the Alzheimer's Disease Neuroimaging Initiative 3. The Journal of Prevention of Alzheimer's Disease. 7: 122-127. PMID 32236401 DOI: 10.14283/jpad.2020.5 |
0.418 |
|
| 2020 |
Insel PS, Mormino EC, Aisen PS, Thompson WK, Donohue MC. Neuroanatomical spread of amyloid β and tau in Alzheimer's disease: implications for primary prevention. Brain Communications. 2: fcaa007. PMID 32140682 DOI: 10.1093/braincomms/fcaa007 |
0.371 |
|
| 2020 |
Vellas B, Bain LJ, Touchon J, Aisen PS. Advancing Alzheimer's Disease Treatment: Lessons from CTAD 2018. The Journal of Prevention of Alzheimer's Disease. 6: 198-203. PMID 31062835 DOI: 10.14283/jpad.2019.11 |
0.386 |
|
| 2020 |
Groh JR, Stage E, Logan PE, Iaccarino L, Joie R, Aisen PS, Eloyan A, Fagan AM, Foroud TM, Gatsonis C, Jack CR, kramer JH, Koeppe RA, Saykin AJ, Toga AW, et al. Sex‐associated differences in pathology burden in early‐onset Alzheimer’s disease Alzheimer's & Dementia. 16. DOI: 10.1002/alz.046532 |
0.309 |
|
| 2020 |
Rabinovici GD, Iaccarino L, La Joie R, Lesman‐Segev OH, Soleimani‐Meigooni DN, Provost K, Collins JA, Aisen PS, Borowski BJ, Eloyan A, Fagan A, Foroud TM, Gatsonis C, Jack CR, Kramer JH, et al. Amyloid and tau PET in sporadic early‐onset Alzheimer’s disease: Preliminary results from LEADS Alzheimer's & Dementia. 16. DOI: 10.1002/alz.041613 |
0.324 |
|
| 2019 |
Michelson D, Grundman M, Magnuson K, Fisher R, Levenson JM, Aisen P, Marek K, Gray M, Hefti F. Randomized, Placebo Controlled Trial of NPT088, A Phage-Derived, Amyloid-Targeted Treatment for Alzheimer's Disease. The Journal of Prevention of Alzheimer's Disease. 6: 228-231. PMID 31686093 DOI: 10.14283/jpad.2019.37 |
0.43 |
|
| 2019 |
Yu JT, Li JQ, Suckling J, Feng L, Pan A, Wang YJ, Song B, Zhu SL, Li DH, Wang HF, Tan CC, Dong Q, Tan L, Mok V, Aisen PS, et al. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 31399333 DOI: 10.1016/J.Jalz.2019.05.006 |
0.349 |
|
| 2019 |
Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, Mahoney E, Cummings JL, Tariot PN, Aisen PS, Vellas B, Lines C, Michelson D. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. Alzheimer's Research & Therapy. 11: 68. PMID 31387606 DOI: 10.1186/S13195-019-0520-1 |
0.463 |
|
| 2019 |
Li D, Iddi S, Aisen PS, Thompson WK, Donohue MC. The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 5: 308-318. PMID 31367671 DOI: 10.1016/J.Trci.2019.04.004 |
0.515 |
|
| 2019 |
van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, ... ... Aisen PS, et al. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. Jama Neurology. PMID 31329216 DOI: 10.1001/Jamaneurol.2019.2050 |
0.753 |
|
| 2019 |
Iddi S, Li D, Aisen PS, Rafii MS, Thompson WK, Donohue MC. Predicting the course of Alzheimer's progression. Brain Informatics. 6: 6. PMID 31254120 DOI: 10.1186/S40708-019-0099-0 |
0.694 |
|
| 2019 |
Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, Schindler R, Weiner M, Zetterberg H, Aisen P, Vellas B. Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. The Journal of Prevention of Alzheimer's Disease. 6: 169-173. PMID 31062827 DOI: 10.14283/jpad.2019.21 |
0.381 |
|
| 2019 |
Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, Salloway S, Sampaio C, Sims JR, Sperling B, Sperling R, Welsh-Bohmer KA, Touchon J, Vellas B, Aisen P. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force. The Journal of Prevention of Alzheimer's Disease. 6: 164-168. PMID 31062826 DOI: 10.14283/jpad.2019.12 |
0.321 |
|
| 2019 |
Cummings J, Blennow K, Johnson K, Keeley M, Bateman RJ, Molinuevo JL, Touchon J, Aisen P, Vellas B. Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force. The Journal of Prevention of Alzheimer's Disease. 6: 157-163. PMID 31062825 DOI: 10.14283/jpad.2019.14 |
0.387 |
|
| 2019 |
Henley D, Raghavan N, Sperling R, Aisen P, Raman R, Romano G. Preliminary Results of a Trial of Atabecestat in Preclinical Alzheimer's Disease. The New England Journal of Medicine. 380: 1483-1485. PMID 30970197 DOI: 10.1056/Nejmc1813435 |
0.637 |
|
| 2019 |
Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, van Dyck CH, Boada M, Zhang Y, Li W, Furtek C, Mahoney E, Harper Mozley L, et al. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. The New England Journal of Medicine. 380: 1408-1420. PMID 30970186 DOI: 10.1056/Nejmoa1812840 |
0.544 |
|
| 2019 |
Sano M, Zhu CW, Kaye J, Mundt JC, Hayes TL, Ferris S, Thomas RG, Sun CK, Jiang Y, Donohue MC, Schneider LS, Egelko S, Aisen PS, Feldman HH. A randomized clinical trial to evaluate home-based assessment of people over 75 years old. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30872114 DOI: 10.1016/J.Jalz.2019.01.007 |
0.368 |
|
| 2019 |
Schott JM, Aisen PS, Cummings JL, Howard RJ, Fox NC. Unsuccessful trials of therapies for Alzheimer's disease. Lancet (London, England). 393: 29. PMID 30614456 DOI: 10.1016/S0140-6736(18)31896-8 |
0.489 |
|
| 2019 |
Vellas B, Touchon J, Aisen P, Carrillo MC. Journal of Prevention of Alzheimer's Disease (JPAD): Building a "Fleet" Against Alzheimer's Disease. The Journal of Prevention of Alzheimer's Disease. 1: 2-3. PMID 29261213 DOI: 10.14283/jpad.2014.22 |
0.408 |
|
| 2019 |
Liu-Seifert H, Siemers E, Selzler K, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. Correlation between Cognition and Function across the Spectrum of Alzheimer's Disease. The Journal of Prevention of Alzheimer's Disease. 3: 138-144. PMID 29205252 DOI: 10.14283/jpad.2016.99 |
0.449 |
|
| 2019 |
Sperling R, Cummings J, Donohue M, Aisen P. Global Alzheimer's Platform Trial Ready Cohorts for the Prevention of Alzheimer's Dementia. The Journal of Prevention of Alzheimer's Disease. 3: 185-187. PMID 29199318 DOI: 10.14283/jpad.2016.108 |
0.572 |
|
| 2019 |
Aisen PS. Continuing Progress in Alzheimer's Disease Trials: Cause for Optimism. The Journal of Prevention of Alzheimer's Disease. 4: 211-212. PMID 29181483 DOI: 10.14283/jpad.2017.34 |
0.391 |
|
| 2019 |
Craft S, Raman R, Chow TW, Rafii MS, Rissman RA, Brewer JB, Donohue MC, Sun C, Harless K, Gessert D, Aisen PS. DT-02-03: OPEN LABEL EXTENSION RESULTS FROM A PHASE II/III TRIAL OF INTRANASAL INSULIN Alzheimer's & Dementia. 15: P1489-P1489. DOI: 10.1016/J.Jalz.2019.08.012 |
0.586 |
|
| 2019 |
Apostolova LG, Iaccarino L, Collins JA, Aisen PS, Borowski BJ, Eloyan A, Fagan AM, Foroud TM, Gatsonis C, Jack CR, Kramer JH, Koeppe RA, Saykin AJ, Toga AW, Vemuri P, et al. P1-349: ADVANCING CLINICAL AND BIOMARKER RESEARCH IN AD: THE LEAD STUDY Alzheimer's & Dementia. 15: P383-P384. DOI: 10.1016/J.Jalz.2019.06.904 |
0.405 |
|
| 2019 |
Gatchel JR, Amariglio R, Sikkes SAM, Donovan NJ, Rentz DM, Sun C, Donohue MC, Aisen PS, Sperling RA, Marshall GA, Team AS. P1-286: Geriatric Depression Scale (Gds) Item-Level Analysis By Amyloid Pet And Cognition: Findings From The Anti-Amyloid Treatment In Asymptomatic Alzheimer'S Disease (A4) Study Screening Data Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.841 |
0.451 |
|
| 2019 |
Sur C, Kost J, Scott D, Adamczuk K, Fox NC, Cummings JL, Tariot PN, Aisen PS, Vellas B, Voss T, Mukai Y, Michelson D, Egan MF. O3‐10‐02: Verubecestat‐Induced Brain Volume Loss Occurs Rapidly And Only In Amyloid‐Enriched Brain Regions In Epoch, A Phase 3 Trial In Mild‐To‐Moderate Alzheimer'S Disease Patients Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4679 |
0.398 |
|
| 2019 |
Egan MF, Kost J, Lines C, Voss T, Mozley LH, Furtek C, Mukai Y, Aisen PS, Cummings JL, Tariot PN, Vellas B, Dupre N, Randolph C, Sur C, Michelson D. Fts3-01-05: Further Analyses Of Cognitive Outcomes In The Apecs Phase-3 Trial Of Verubecestat In Prodromal Ad Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4622 |
0.432 |
|
| 2019 |
Henley D, Sperling RA, Aisen PS, Raman R, Donohue MC, Ernstrom K, Shi Y, Karcher K, Raghavan N, Tymofyeyev Y, Brashear R, Novak GP, Thipphawong J, Saad Z, Kolb HC, et al. FTS3-01-04: FINAL EFFICACY, SAFETY AND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZHEIMER'S DISEASE Alzheimer's & Dementia. 15: P873-P874. DOI: 10.1016/J.Jalz.2019.06.4621 |
0.564 |
|
| 2019 |
Amariglio R, Sikkes SAM, Marshall GA, Buckley RF, Gatchel JR, Johnson KA, Rentz DM, Donohue MC, Raman R, Sun C, Aisen PS, Sperling RA. Item-Level Comparison Of Participant And Study Partner Report On The Cognitive Function Index By Amyloid Pet From The A4 Study Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.4370 |
0.345 |
|
| 2019 |
Marshall GA, Sikkes SAM, Amariglio R, Gatchel JR, Rentz D, Johnson KA, Langford O, Sun C, Donohue MC, Raman R, Aisen PS, Sperling RA, Galasko DR, Team AS. P4-245: The Association Between Instrumental Activities Of Daily Living And Cortical Amyloid In Cognitively Normal Older Adults Screening For The A4 Study Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.3908 |
0.323 |
|
| 2019 |
Li D, Iddi S, Aisen PS, Thompson WK, Donohue MC. P4-024: The Relative Efficiency Of Time-To-Progression And Continuous Measures Of Cognition In Preclinical Alzheimer'S Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.3683 |
0.429 |
|
| 2019 |
Molinuevo JL, Hansson O, Batrla-Utermann R, Bittner T, Aisen PS, Baldor R, Carlsson C, Grief S, Monsch AU, Reiman EM, Vilaseca J, Weiner MW, Simon M, Stutz V, Wahl S, et al. P3-239: Optimized Pathways For Early Detection Of Alzheimer'S Disease With Blood-Based Biomarkers Alzheimers & Dementia. 15. DOI: 10.1016/J.Jalz.2019.06.3269 |
0.404 |
|
| 2018 |
Rafii MS, Aisen PS. Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. Cns Drugs. PMID 30560544 DOI: 10.1007/S40263-018-0598-1 |
0.739 |
|
| 2018 |
Hurtz S, Chow N, Watson AE, Somme JH, Goukasian N, Hwang KS, Morra J, Elashoff D, Gao S, Petersen RC, Aisen PS, Thompson PM, Apostolova LG. Automated and manual hippocampal segmentation techniques: Comparison of results, reproducibility and clinical applicability. Neuroimage. Clinical. 101574. PMID 30553759 DOI: 10.1016/J.Nicl.2018.10.012 |
0.342 |
|
| 2018 |
Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC. Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 657-668. PMID 30456292 DOI: 10.1016/J.Dadm.2018.07.008 |
0.728 |
|
| 2018 |
Veitch DP, Weiner MW, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ, et al. Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30321505 DOI: 10.1016/J.Jalz.2018.08.005 |
0.575 |
|
| 2018 |
Sano M, Egelko S, Zhu CW, Li C, Donohue MC, Ferris S, Kaye J, Mundt JC, Sun CK, Aisen PS, Feldman HH. Participant satisfaction with dementia prevention research: Results from Home-Based Assessment trial. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 30297140 DOI: 10.1016/J.Jalz.2018.05.016 |
0.381 |
|
| 2018 |
Coley N, Raman R, Donohue MC, Aisen PS, Vellas B, Andrieu S. Defining the Optimal Target Population for Trials of Polyunsaturated Fatty Acid Supplementation Using the Erythrocyte Omega-3 Index: A Step Towards Personalized Prevention of Cognitive Decline? The Journal of Nutrition, Health & Aging. 22: 982-998. PMID 30272103 DOI: 10.1007/S12603-018-1052-2 |
0.339 |
|
| 2018 |
Lawlor B, Segurado R, Kennelly S, Olde Rikkert MGM, Howard R, Pasquier F, Börjesson-Hanson A, Tsolaki M, Lucca U, Molloy DW, Coen R, Riepe MW, Kálmán J, Kenny RA, Cregg F, ... ... Aisen P, et al. Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. Plos Medicine. 15: e1002660. PMID 30248105 DOI: 10.1371/Journal.Pmed.1002660 |
0.532 |
|
| 2018 |
Iddi S, Li D, Aisen PS, Rafii MS, Litvan I, Thompson WK, Donohue MC. Estimating the Evolution of Disease in the Parkinson's Progression Markers Initiative. Neuro-Degenerative Diseases. 18: 173-190. PMID 30089306 DOI: 10.1159/000488780 |
0.681 |
|
| 2018 |
Liu-Seifert H, Siemers E, Sundell K, Mynderse M, Cummings J, Mohs R, Aisen P. Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer's Disease in EXPEDITION 3. The Journal of Prevention of Alzheimer's Disease. 5: 184-187. PMID 29972211 DOI: 10.14283/jpad.2018.22 |
0.386 |
|
| 2018 |
Aisen PS, Siemers E, Michelson D, Salloway S, Sampaio C, Carrillo MC, Sperling R, Doody R, Scheltens P, Bateman R, Weiner M, Vellas B. What Have We Learned from Expedition III and EPOCH Trials? Perspective of the CTAD Task Force. The Journal of Prevention of Alzheimer's Disease. 5: 171-174. PMID 29972209 DOI: 10.14283/jpad.2018.23 |
0.37 |
|
| 2018 |
Chen YF, Ni X, Fleisher AS, Zhou W, Aisen P, Mohs R. A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 4: 46-53. PMID 29955651 DOI: 10.1016/J.Trci.2017.12.002 |
0.496 |
|
| 2018 |
Iwatsubo T, Iwata A, Suzuki K, Ihara R, Arai H, Ishii K, Senda M, Ito K, Ikeuchi T, Kuwano R, Matsuda H, Sun CK, Beckett LA, Petersen RC, ... ... Aisen PS, et al. Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 29753531 DOI: 10.1016/J.Jalz.2018.03.009 |
0.516 |
|
| 2018 |
Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Sur C, Mukai Y, Voss T, Furtek C, Mahoney E, Harper Mozley L, Vandenberghe R, Mo Y, Michelson D. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. The New England Journal of Medicine. 378: 1691-1703. PMID 29719179 DOI: 10.1056/Nejmoa1706441 |
0.422 |
|
| 2018 |
Cummings J, Fox N, Vellas B, Aisen P, Shan G. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force. The Journal of Prevention of Alzheimer's Disease. 5: 103-109. PMID 29616703 DOI: 10.14283/jpad.2018.13 |
0.376 |
|
| 2018 |
Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS. Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. Jama Neurology. PMID 29582053 DOI: 10.1001/Jamaneurol.2018.0233 |
0.748 |
|
| 2018 |
Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, Siemers E. Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease. The Journal of Prevention of Alzheimer's Disease. 5: 8-14. PMID 29405226 DOI: 10.14283/jpad.2018.1 |
0.366 |
|
| 2018 |
Klinger RY, James OG, Borges-Neto S, Bisanar T, Li YJ, Qi W, Berger M, Terrando N, Newman MF, Doraiswamy PM, Mathew JP, Weiner MW, Aisen P, Weiner M, Aisen P, ... ... Aisen P, ... ... Aisen P, ... ... Aisen P, ... ... Aisen P, et al. 18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery. Anesthesiology. PMID 29389750 DOI: 10.1097/Aln.0000000000002103 |
0.41 |
|
| 2018 |
Aisen PS. Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. 90: 145. PMID 29335309 DOI: 10.1212/Wnl.0000000000004821 |
0.494 |
|
| 2018 |
Egan MF, Voss T, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, Dyck CHv, Sur C, Mukai Y, Furtek C, Mahoney EM, Mozley LH, Mo Y, Michelson D. P4-013: Design Of A Phase-3 Trial (Apecs) To Evaluate The Bace Inhibitor Verubecestat In Prodromal Ad Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2415 |
0.394 |
|
| 2018 |
Sperling RA, Donohue MC, Raman R, Sun C, Yaari R, Siemers ER, Johnson KA, Aisen PS. O1-02-02: The Anti-Amyloid Treatment In Asymptomatic Alzheimer'S Disease (A4) Study: Report Of Screening Data Results Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2337 |
0.418 |
|
| 2018 |
Grill JD, Sultzer DL, Burns JM, Ernstrom K, Raman R, Donohue MC, Johnson KA, Aisen PS, Sperling RA, Karlawish J. O1-02-01: Impact Of Disclosing Amyloid Imaging Results To Cognitively Normal Research Participants: The A4 Experience Alzheimers & Dementia. 14. DOI: 10.1016/J.Jalz.2018.06.2336 |
0.315 |
|
| 2018 |
Morin R, Bickford DD, Au YH, Scherer KB, Catalinotto DC, Insel P, Tosun D, Zmuda M, Toga AW, Aisen PS, Raman R, Saykin A, Weiner M, Butters MA, Nelson C, et al. Association of Subjective Cognitive Complaints and Objective Cognitive Impairment in Late Life Depression The American Journal of Geriatric Psychiatry. 26: S90-S91. DOI: 10.1016/J.Jagp.2018.01.110 |
0.305 |
|
| 2017 |
Touchon J, Rosenbaum J, Aisen P, Andrieu S, Carrillo MC, Ceccaldi M, Dartiques JF, Feldman H, Gabelle A, Isaac M, Fitten LJ, Sperling RA, Vellas B, Tariot P, Weiner M. Editorial: Collaborative Efforts to Prevent Alzheimer's Disease. The Journal of Nutrition, Health & Aging. 21: 1072-1074. PMID 29188862 DOI: 10.1007/S12603-017-0961-9 |
0.465 |
|
| 2017 |
Aisen P, Touchon J, Amariglio R, Andrieu S, Bateman R, Breitner J, Donohue M, Dunn B, Doody R, Fox N, Gauthier S, Grundman M, Hendrix S, Ho C, Isaac M, et al. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. The Journal of Prevention of Alzheimer's Disease. 4: 116-124. PMID 29186281 DOI: 10.14283/jpad.2017.13 |
0.346 |
|
| 2017 |
Donohue MC, Aisen PS. Elevated Brain Amyloid in Cognitively Normal Individuals-Reply. Jama. 318: 1393-1394. PMID 29049582 DOI: 10.1001/Jama.2017.12962 |
0.365 |
|
| 2017 |
Horgusluoglu-Moloch E, Nho K, Risacher SL, Kim S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR, Lovestone S, Simmons A, Weiner MW, Saykin AJ. Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. Neurobiology of Aging. 60: 92-103. PMID 28941407 DOI: 10.1016/J.Neurobiolaging.2017.08.010 |
0.458 |
|
| 2017 |
Li C, Neugroschl J, Luo X, Zhu C, Aisen P, Ferris S, Sano M. The Utility of the Cognitive Function Instrument (CFI) to Detect Cognitive Decline in Non-Demented Older Adults. Journal of Alzheimer's Disease : Jad. PMID 28854503 DOI: 10.3233/Jad-161294 |
0.314 |
|
| 2017 |
Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B. On the path to 2025: understanding the Alzheimer's disease continuum. Alzheimer's Research & Therapy. 9: 60. PMID 28793924 DOI: 10.1186/S13195-017-0283-5 |
0.63 |
|
| 2017 |
Weiner MW, Harvey D, Hayes J, Landau SM, Aisen PS, Petersen RC, Tosun D, Veitch DP, Jack CR, Decarli C, Saykin AJ, Grafman J, Neylanthe TC. Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report. Alzheimer's & Dementia (New York, N. Y.). 3: 177-188. PMID 28758146 DOI: 10.1016/J.Trci.2017.02.005 |
0.454 |
|
| 2017 |
Donohue MC, Sun CK, Raman R, Insel PS, Aisen PS. Cross-validation of optimized composites for preclinical Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 3: 123-129. PMID 28758145 DOI: 10.1016/J.Trci.2016.12.001 |
0.343 |
|
| 2017 |
Donohue MC, Sperling RA, Petersen R, Sun CK, Weiner MW, Aisen PS. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. Jama. 317: 2305-2316. PMID 28609533 DOI: 10.1001/Jama.2017.6669 |
0.528 |
|
| 2017 |
Nho K, Kim S, Horgusluoglu E, Risacher SL, Shen L, Kim D, Lee S, Foroud T, Shaw LM, Trojanowski JQ, Aisen PS, Petersen RC, Jack CR, Weiner MW, Green RC, et al. Association analysis of rare variants near the APOE region with CSF and neuroimaging biomarkers of Alzheimer's disease. Bmc Medical Genomics. 10: 29. PMID 28589856 DOI: 10.1186/S12920-017-0267-0 |
0.385 |
|
| 2017 |
Liu-Seifert H, Andersen S, Case M, Sparks J, Holdridge KC, Wessels AM, Hendrix S, Aisen P, Siemers E. Statistical properties of continuous composite scales and implications for drug development. Journal of Biopharmaceutical Statistics. PMID 28402165 DOI: 10.1080/10543406.2017.1315819 |
0.359 |
|
| 2017 |
Petersen RC, Thomas RG, Aisen PS, Mohs RC, Carrillo MC, Albert MS. Randomized controlled trials in mild cognitive impairment: Sources of variability. Neurology. PMID 28381516 DOI: 10.1212/Wnl.0000000000003907 |
0.369 |
|
| 2017 |
Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. PMID 28381506 DOI: 10.1212/Wnl.0000000000003904 |
0.804 |
|
| 2017 |
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ, et al. Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28342697 DOI: 10.1016/J.Jalz.2016.11.007 |
0.511 |
|
| 2017 |
Tosun D, Landau S, Aisen PS, Petersen RC, Mintun M, Jagust W, Weiner MW. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals. Brain : a Journal of Neurology. PMID 28334939 DOI: 10.1093/Brain/Awx046 |
0.405 |
|
| 2017 |
Mormino EC, Papp KV, Rentz DM, Donohue MC, Amariglio R, Quiroz YT, Chhatwal J, Marshall GA, Donovan N, Jackson J, Gatchel JR, Hanseeuw BJ, Schultz AP, Aisen PS, Johnson KA, et al. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated β-amyloid. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 28253478 DOI: 10.1016/J.Jalz.2017.01.018 |
0.617 |
|
| 2017 |
Moussa C, Hebron M, Huang X, Ahn J, Rissman RA, Aisen PS, Turner RS. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. Journal of Neuroinflammation. 14: 1. PMID 28086917 DOI: 10.1186/S12974-016-0779-0 |
0.682 |
|
| 2017 |
Reiman EM, Kuang X, Luo J, Chen Y, Thiyyagura P, Bauer R, Lee W, Protas H, Goradia DD, Aisen PS, Johnson K, Langbaum JB, Sperling RA, Tariot P, Jagust WJ, et al. [IC-P-041]: SAMPLE SIZES FOR 24-MONTH ALZHEIMER's PREVENTION TRIALS USING BIOMARKER ENDPOINTS IN COGNITIVELY UNIMPAIRED AMYLOID-POSITIVE ADULTS Alzheimer's & Dementia. 13: P36-P37. DOI: 10.1016/J.Jalz.2017.06.2313 |
0.443 |
|
| 2017 |
Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, Siemers ER. Delayed-Start Analyses In The Phase 3 Solanezumab Expedition3 Study In Mild Alzheimer’S Disease Alzheimers & Dementia. 13: 1260. DOI: 10.1016/J.Jalz.2017.06.1881 |
0.355 |
|
| 2016 |
Aisen P, Touchon J, Andrieu S, Boada M, Doody R, Nosheny RL, Langbaum JB, Schneider L, Hendrix S, Wilcock G, Molinuevo JL, Ritchie C, Ousset PJ, Cummings J, Sperling R, et al. Registries and Cohorts to Accelerate Early Phase Alzheimer's Trials. A Report from the E.U./U.S. Clinical Trials in Alzheimer's Disease Task Force. The Journal of Prevention of Alzheimer's Disease. 3: 68-74. PMID 29210442 DOI: 10.14283/jpad.2016.97 |
0.382 |
|
| 2016 |
Gelmont D, Thomas RG, Britt J, Dyck-Jones JA, Doralt J, Fritsch S, Brewer JB, Rissman RA, Aisen P. Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease. Alzheimer's & Dementia (New York, N. Y.). 2: 131-139. PMID 29067300 DOI: 10.1016/J.Trci.2016.06.003 |
0.642 |
|
| 2016 |
Cummings J, Aisen P, Barton R, Bork J, Doody R, Dwyer J, Egan JC, Feldman H, Lappin D, Truyen L, Salloway S, Sperling R, Vradenburg G. Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network. The Journal of Prevention of Alzheimer's Disease. 3: 114-120. PMID 28459045 DOI: 10.14283/jpad.2016.93 |
0.493 |
|
| 2016 |
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Salazar J, Saykin AJ, Shaw LM, Toga AW, et al. The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 27931796 DOI: 10.1016/J.Jalz.2016.10.006 |
0.568 |
|
| 2016 |
Sokolow S, Li X, Chen L, D Taylor K, Rotter JI, Rissman RA, Aisen PS, Apostolova LG. Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. Journal of Alzheimer's Disease : Jad. PMID 27911294 DOI: 10.3233/Jad-160562 |
0.651 |
|
| 2016 |
Insel PS, Donohue MC, Mackin RS, Aisen PS, Hansson O, Weiner MW, Mattsson N. Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment. Neurobiology of Aging. 48: 172-181. PMID 27710807 DOI: 10.1016/J.Neurobiolaging.2016.08.017 |
0.445 |
|
| 2016 |
Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer's disease: the path to 2025. Alzheimer's Research & Therapy. 8: 39. PMID 27646601 DOI: 10.1186/S13195-016-0207-9 |
0.497 |
|
| 2016 |
Nho K, Horgusluoglu E, Kim S, Risacher SL, Kim D, Foroud T, Aisen PS, Petersen RC, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, Saykin AJ, et al. Integration of bioinformatics and imaging informatics for identifying rare PSEN1 variants in Alzheimer's disease. Bmc Medical Genomics. 9: 30. PMID 27535542 DOI: 10.1186/S12920-016-0190-9 |
0.394 |
|
| 2016 |
Yassine HN, Rawat V, Mack WJ, Quinn JF, Yurko-Mauro K, Bailey-Hall E, Aisen PS, Chui HC, Schneider LS. The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease. Alzheimer's Research & Therapy. 8: 25. PMID 27358067 DOI: 10.1186/S13195-016-0194-X |
0.525 |
|
| 2016 |
Sano M, Aisen PS, Andrews HF, Tsai WY, Lai F, Dalton AJ. Vitamin E in aging persons with Down syndrome: A randomized, placebo-controlled clinical trial. Neurology. PMID 27164691 DOI: 10.1212/Wnl.0000000000002714 |
0.33 |
|
| 2016 |
Insel PS, Mattsson N, Mackin RS, Schöll M, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Jagust WJ, Weiner MW. Accelerating rates of cognitive decline and imaging markers associated with β-amyloid pathology. Neurology. PMID 27164667 DOI: 10.1212/Wnl.0000000000002683 |
0.349 |
|
| 2016 |
Weninger S, Carrillo MC, Dunn B, Aisen PS, Bateman RJ, Kotz JD, Langbaum JB, Mills SL, Reiman EM, Sperling R, Santacruz AM, Tariot PN, Welsh-Bohmer KA. Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 12: 631-2. PMID 27157073 DOI: 10.1016/J.Jalz.2016.04.001 |
0.627 |
|
| 2016 |
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 12: 292-323. PMID 27012484 DOI: 10.1016/J.Jalz.2016.02.002 |
0.588 |
|
| 2016 |
Rentz DM, Dekhtyar M, Sherman J, Burnham S, Blacker D, Aghjayan SL, Papp KV, Amariglio RE, Schembri A, Chenhall T, Maruff P, Aisen P, Hyman BT, Sperling RA. The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials. The Journal of Prevention of Alzheimer's Disease. 3: 8-12. PMID 26998469 DOI: 10.14283/jpad.2015.78 |
0.432 |
|
| 2016 |
Thomas RG, Albert M, Petersen RC, Aisen PS. Longitudinal decline in mild-to-moderate Alzheimer's disease: Analyses of placebo data from clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 26917500 DOI: 10.1016/J.Jalz.2016.01.002 |
0.537 |
|
| 2016 |
Egan M, Voss T, Mo Y, Mukai Y, Furtek C, Kost J, Aisen PS, Cummings JL, Tariot PN, Vellas B, Michelson D. Bace Inhibitor Verubecestat (Mk-8931): Baseline Characteristics For Participants Enrolled In The Phase Ii/Iii Epoch Alzheimer’S Disease Trial Alzheimers & Dementia. 12: 1183. DOI: 10.1016/J.Jalz.2016.07.126 |
0.352 |
|
| 2016 |
Sokolow S, Chen L, Do T, Li X, Taylor K, Rotter JI, Rissman RA, Aisen PS, Apostolova LG. Damaging Effect Of The Butyrylcholinesterase K-Variant In Donepezil Therapy Of Mild Cognitive Impairment Alzheimers & Dementia. 12: 421. DOI: 10.1016/J.Jalz.2016.06.799 |
0.3 |
|
| 2016 |
Aisen PS, Cummings JL, Sperling RA. F5-04-03: TRC-PAD: Using Run-In Data for Screen Failure Reduction Alzheimer's & Dementia. 12: P372-P372. DOI: 10.1016/J.Jalz.2016.06.697 |
0.377 |
|
| 2016 |
E-H Moussa C, Hebron M, Huang X, Brown HJ, Rissman RA, Aisen PS, Turner RS. O4-08-04: Resveratrol Activates the CNS SIRTUIN1/Matrix Mettaloproteinase-9 Pathway and Regulates Neuroinflammation in Alzheimer's Disease Alzheimer's & Dementia. 12: P352-P352. DOI: 10.1016/J.Jalz.2016.06.652 |
0.382 |
|
| 2016 |
Sperling RA, Aisen PS. F4-03-03: Anti-Amyloid Treatment of Asymptomatic Ad: A4 and Beyond Alzheimer's & Dementia. 12: P326-P327. DOI: 10.1016/J.Jalz.2016.06.598 |
0.498 |
|
| 2016 |
Weninger S, Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman R, Morris JC, Sperling RA, Aisen PS, Roses AD, Welsh-Bohmer KA, Carrillo M. F4-03-01: Collaboration for Alzheimer's Prevention (CAP): Advancing the Evaluation of Preclinical Alzheimer's Disease Treatments Alzheimer's & Dementia. 12: P325-P326. DOI: 10.1016/J.Jalz.2016.06.596 |
0.477 |
|
| 2015 |
Liu-Seifert H, Siemers E, Holdridge KC, Andersen SW, Lipkovich I, Carlson C, Sethuraman G, Hoog S, Hayduk R, Doody R, Aisen P. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. Alzheimer's & Dementia (New York, N. Y.). 1: 111-121. PMID 29854931 DOI: 10.1016/j.trci.2015.06.006 |
0.464 |
|
| 2015 |
Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, Sundell K, Stern Y, Rentz DM, Dubois B, Jones RW, Cummings J, Aisen PS. A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS). The Journal of Prevention of Alzheimer's Disease. 2: 227-241. PMID 27019841 DOI: 10.14283/jpad.2015.82 |
0.402 |
|
| 2015 |
Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Frontiers in Behavioral Neuroscience. 9: 239. PMID 26441570 DOI: 10.3389/Fnbeh.2015.00239 |
0.78 |
|
| 2015 |
Reiman EM, Langbaum JB, Tariot PN, Lopera F, Bateman RJ, Morris JC, Sperling RA, Aisen PS, Roses AD, Welsh-Bohmer KA, Carrillo MC, Weninger S. CAP-advancing the evaluation of preclinical Alzheimer disease treatments. Nature Reviews. Neurology. PMID 26416539 DOI: 10.1038/Nrneurol.2015.177 |
0.62 |
|
| 2015 |
Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. Journal of Alzheimer's Disease : Jad. 47: 205-14. PMID 26402769 DOI: 10.3233/Jad-142508 |
0.491 |
|
| 2015 |
Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, Garaci F, Toschi N, Habert MO, Blennow K, Zetterberg H, O'Bryant SE, Johnson L, Galluzzi S, Bokde AL, ... ... Aisen PS, et al. Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease : Jad. PMID 26402088 DOI: 10.3233/Jad-150202 |
0.49 |
|
| 2015 |
Turner RS, Thomas RG, Craft S, van Dyck CH, Mintzer J, Reynolds BA, Brewer JB, Rissman RA, Raman R, Aisen PS. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. PMID 26362286 DOI: 10.1212/Wnl.0000000000002035 |
0.643 |
|
| 2015 |
Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, McDonald BC, Yoder KK, Hutchins GD, West JD, Tallman EF, Gao S, Foroud TM, Farlow MR, De Jager PL, Bennett DA, ... Aisen PS, et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer's disease implicates microglial activation gene IL1RAP. Brain : a Journal of Neurology. PMID 26268530 DOI: 10.1093/Brain/Awv231 |
0.482 |
|
| 2015 |
Vellas B, Bateman R, Blennow K, Frisoni G, Johnson K, Katz R, Langbaum J, Marson D, Sperling R, Wessels A, Salloway S, Doody R, Aisen P. Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force. The Journal of Prevention of Alzheimer's Disease. 2: 128-135. PMID 26247004 DOI: 10.14283/jpad.2015.55 |
0.537 |
|
| 2015 |
Sacuiu S, Insel PS, Mueller S, Tosun D, Mattsson N, Jack CR, DeCarli C, Petersen R, Aisen PS, Weiner MW, Mackin RS. Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. PMID 26238228 DOI: 10.1016/J.Jagp.2015.03.006 |
0.429 |
|
| 2015 |
Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. The Lancet. Neurology. 14: 926-44. PMID 26213339 DOI: 10.1016/S1474-4422(15)00153-2 |
0.46 |
|
| 2015 |
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Donohue MC, Green RC, Harvey D, Jack CR, Jagust W, Morris JC, Petersen RC, Saykin AJ, Shaw L, et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 865-84. PMID 26194320 DOI: 10.1016/J.Jalz.2015.04.005 |
0.578 |
|
| 2015 |
Beckett LA, Donohue MC, Wang C, Aisen P, Harvey DJ, Saito N. The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 823-31. PMID 26194315 DOI: 10.1016/J.Jalz.2015.05.004 |
0.474 |
|
| 2015 |
Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, Waligorska T, Brylska M, Fields L, Shah N, Soares H, Dean RA, Vanderstichele H, Petersen RC, Aisen PS, et al. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 772-91. PMID 26194312 DOI: 10.1016/J.Jalz.2015.05.003 |
0.541 |
|
| 2015 |
Aisen PS, Petersen RC, Donohue M, Weiner MW. Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: 734-9. PMID 26194309 DOI: 10.1016/J.Jalz.2015.05.005 |
0.525 |
|
| 2015 |
Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, Aisen P, Raman R, Miller DS, Hake AM, Cummings J. Alzheimer's disease progression by geographical region in a clinical trial setting. Alzheimer's Research & Therapy. 7: 43. PMID 26120369 DOI: 10.1186/S13195-015-0127-0 |
0.544 |
|
| 2015 |
Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, Liu-Seifert H, Hake AM, Miller DS, Doody RS, Henley DB, Cummings JL. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. Alzheimer's Research & Therapy. 7: 39. PMID 26120368 DOI: 10.1186/S13195-015-0122-5 |
0.431 |
|
| 2015 |
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Cedarbaum J, Green RC, Harvey D, Jack CR, Jagust W, Luthman J, Morris JC, Petersen RC, Saykin AJ, Shaw L, et al. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 11: e1-e120. PMID 26073027 DOI: 10.1016/J.Jalz.2014.11.001 |
0.541 |
|
| 2015 |
Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, Farlow M, Iwatsubo T, Vellas B, Sun X, Ernstrom K, Thomas RG, Aisen PS. Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease. Alzheimer's Research & Therapy. 7: 36. PMID 26064192 DOI: 10.1186/S13195-015-0121-6 |
0.572 |
|
| 2015 |
Insel PS, Mattsson N, Mackin RS, Kornak J, Nosheny R, Tosun-Turgut D, Donohue MC, Aisen PS, Weiner MW. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Annals of Clinical and Translational Neurology. 2: 534-47. PMID 26000325 DOI: 10.1002/Acn3.192 |
0.483 |
|
| 2015 |
Risacher SL, Kim S, Nho K, Foroud T, Shen L, Petersen RC, Jack CR, Beckett LA, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ, et al. APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 25960448 DOI: 10.1016/J.Jalz.2015.03.003 |
0.422 |
|
| 2015 |
Rafii MS, Aisen PS. Advances in Alzheimer's disease drug development. Bmc Medicine. 13: 62. PMID 25857341 DOI: 10.1186/S12916-015-0297-4 |
0.758 |
|
| 2015 |
Mattsson N, Insel PS, Donohue M, Jagust W, Sperling R, Aisen P, Weiner MW. Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls. Jama Neurology. 72: 554-60. PMID 25775167 DOI: 10.1001/Jamaneurol.2014.4530 |
0.591 |
|
| 2015 |
Amariglio RE, Donohue MC, Marshall GA, Rentz DM, Salmon DP, Ferris SH, Karantzoulis S, Aisen PS, Sperling RA. Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. Jama Neurology. 72: 446-54. PMID 25706191 DOI: 10.1001/Jamaneurol.2014.3375 |
0.656 |
|
| 2015 |
Mattsson N, Insel PS, Aisen PS, Jagust W, Mackin S, Weiner M. Brain structure and function as mediators of the effects of amyloid on memory. Neurology. 84: 1136-44. PMID 25681451 DOI: 10.1212/Wnl.0000000000001375 |
0.381 |
|
| 2015 |
Nho K, Kim S, Risacher SL, Shen L, Corneveaux JJ, Swaminathan S, Lin H, Ramanan VK, Liu Y, Foroud TM, Inlow MH, Siniard AL, Reiman RA, Aisen PS, Petersen RC, et al. Protective variant for hippocampal atrophy identified by whole exome sequencing. Annals of Neurology. 77: 547-52. PMID 25559091 DOI: 10.1002/Ana.24349 |
0.392 |
|
| 2015 |
Hampel H, Schneider LS, Giacobini E, Kivipelto M, Sindi S, Dubois B, Broich K, Nisticò R, Aisen PS, Lista S. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future. Expert Review of Neurotherapeutics. 15: 83-105. PMID 25537424 DOI: 10.1586/14737175.2015.995637 |
0.544 |
|
| 2015 |
Nosheny RL, Insel PS, Truran D, Schuff N, Jack CR, Aisen PS, Shaw LM, Trojanowski JQ, Weiner MW. Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment. Neurobiology of Aging. 36: 273-82. PMID 25175807 DOI: 10.1016/J.Neurobiolaging.2014.07.036 |
0.437 |
|
| 2015 |
Liu-Seifert H, Siemers E, Sundell K, Price K, Han B, Selzler K, Aisen P, Cummings J, Raskin J, Mohs R. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. Journal of Alzheimer's Disease : Jad. 43: 949-55. PMID 25125457 DOI: 10.3233/Jad-140792 |
0.475 |
|
| 2015 |
Leduc V, De Beaumont L, Théroux L, Dea D, Aisen P, Petersen RC, Dufour R, Poirier J. HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study. Molecular Psychiatry. 20: 867-73. PMID 25023145 DOI: 10.1038/Mp.2014.81 |
0.499 |
|
| 2015 |
Liu-Seifert H, Siemers E, Holdridge KC, Andersen SW, Lipkovich I, Carlson C, Sethuraman G, Hoog S, Hayduk R, Doody R, Aisen P. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years Alzheimer's and Dementia: Translational Research and Clinical Interventions. 1: 111-121. DOI: 10.1016/J.Trci.2015.06.006 |
0.53 |
|
| 2015 |
Ramanan VK, Risacher SL, Nho K, Kim S, Shen L, Foroud TM, Aisen PS, Petersen RC, Toga AW, Green RC, Jagust WJ, Weiner MW, Saykin AJ. Gwas of longitudinal amyloid PET identifies IL1RAP as a new potential Alzheimer's disease target Alzheimers & Dementia. 11. DOI: 10.1016/J.Jalz.2015.07.369 |
0.47 |
|
| 2015 |
Liu-Seifert H, Aisen PS, Andersen SW, Holdridge KC, Siemers ER. Delayed-start analyses of up to 3.5 years in the phase 3 solanezumab expedition program in mild Alzheimer's disease Alzheimers & Dementia. 11. DOI: 10.1016/J.Jalz.2015.07.338 |
0.416 |
|
| 2015 |
Sperling RA, Karlawish J, Grill JD, Burns JM, Sultzer D, Johnson KA, Aisen PS. F3-03-03: Disclosure of amyloid status in the a4 trial Alzheimer's & Dementia. 11: P215-P215. DOI: 10.1016/J.Jalz.2015.07.232 |
0.458 |
|
| 2015 |
Nho K, Kim S, Risacher SL, Foroud TM, Aisen PS, Petersen RC, Jagust WJ, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, Greicius MD, Saykin AJ. P3-014: Influence of rare RELN
variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer's disease Alzheimer's & Dementia. 11: P624-P625. DOI: 10.1016/j.jalz.2015.06.880 |
0.307 |
|
| 2015 |
Insel PS, Mattsson N, Mackin S, Kornak J, Nosheny RL, Tosun D, Donohue MC, Aisen PS, Weiner MW. P4-135: Inclusion criteria and cognitive responses to optimize trials in Alzheimer's disease Alzheimer's & Dementia. 11: P829-P830. DOI: 10.1016/J.Jalz.2015.06.1841 |
0.49 |
|
| 2015 |
Nho K, Kim S, Risacher SL, Foroud TM, Aisen PS, Petersen RC, Jagust WJ, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW, Green RC, Toga AW, Greicius MD, Saykin AJ. IC-P-042: Influence of rare reelin variants on quantitative PET imaging and CSF phenotypes in late-onset Alzheimer's disease Alzheimer's & Dementia. 11: P36-P36. DOI: 10.1016/J.Jalz.2015.06.062 |
0.399 |
|
| 2015 |
Risacher SL, Kim S, Nho K, Jack CR, Jagust WJ, Aisen PS, Petersen RC, Weiner MW, Saykin AJ. Association of cerebral microhemorrhages with amyloid deposition and hyperlipidemia Alzheimers & Dementia. 11. DOI: 10.1016/J.Jalz.2015.06.057 |
0.305 |
|
| 2015 |
Aisen PS, Petersen RC, Donohue M, Weiner MW. Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans Alzheimer's and Dementia. 11: 734-739. DOI: 10.1016/j.jalz.2015.05.005 |
0.375 |
|
| 2014 |
Vellas B, Sampaio C, Bateman R, Boxer A, Carrillo MC, Cummings J, Dubois B, Hampel H, Katz R, Khachaturian Z, Gauthier S, Johnson K, Karlawish J, Mintun M, Petersen R, ... ... Aisen P, et al. EU./U.S. CTAD Task Force on Alzheimer's Trial Populations. The Journal of Prevention of Alzheimer's Disease. 1: 110-116. PMID 29255837 DOI: 10.14283/jpad.2014.6 |
0.715 |
|
| 2014 |
Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, et al. The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations. The Journal of Prevention of Alzheimer's Disease. 1: 181-202. PMID 26478889 DOI: 10.14283/jpad.2014.32 |
0.58 |
|
| 2014 |
Banks SJ, Raman R, He F, Salmon DP, Ferris S, Aisen P, Cummings J. The Alzheimer's disease cooperative study prevention instrument project: longitudinal outcome of behavioral measures as predictors of cognitive decline. Dementia and Geriatric Cognitive Disorders Extra. 4: 509-16. PMID 25685141 DOI: 10.1159/000357775 |
0.468 |
|
| 2014 |
Insel PS, Mattsson N, Donohue MC, Mackin RS, Aisen PS, Jack CR, Shaw LM, Trojanowski JQ, Weiner MW. The transitional association between β-amyloid pathology and regional brain atrophy. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 25499535 DOI: 10.1016/J.Jalz.2014.11.002 |
0.463 |
|
| 2014 |
Rueda AD, Lau KM, Saito N, Harvey D, Risacher SL, Aisen PS, Petersen RC, Saykin AJ, Tomaszewski Farias S. Self-rated and informant-rated everyday function in comparison to objective markers of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 25449531 DOI: 10.1016/J.Jalz.2014.09.002 |
0.428 |
|
| 2014 |
Ramanan VK, Nho K, Shen L, Risacher SL, Kim S, McDonald BC, Farlow MR, Foroud TM, Gao S, Soininen H, K?oszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, ... Aisen PS, et al. FASTKD2 is associated with memory and hippocampal structure in older adults. Molecular Psychiatry. PMID 25385369 DOI: 10.1038/Mp.2014.142 |
0.303 |
|
| 2014 |
Fargo KN, Aisen P, Albert M, Au R, Corrada MM, DeKosky S, Drachman D, Fillit H, Gitlin L, Haas M, Herrup K, Kawas C, Khachaturian AS, Khachaturian ZS, et al. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: S430-52. PMID 25341459 DOI: 10.1016/J.Jalz.2014.08.103 |
0.568 |
|
| 2014 |
Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen PS, Rissman RA. Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 25301682 DOI: 10.1016/J.Jalz.2014.07.156 |
0.686 |
|
| 2014 |
Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, Frommelt P, Ghetti B, Langbaum JB, Lopera F, Martins R, Masters CL, Mayeux RP, McDade E, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 83: 253-60. PMID 24928124 DOI: 10.1212/Wnl.0000000000000596 |
0.461 |
|
| 2014 |
Weiner MW, Veitch DP, Hayes J, Neylan T, Grafman J, Aisen PS, Petersen RC, Jack C, Jagust W, Trojanowski JQ, Shaw LM, Saykin AJ, Green RC, Harvey D, Toga AW, et al. Effects of traumatic brain injury and posttraumatic stress disorder on Alzheimer's disease in veterans, using the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: S226-35. PMID 24924673 DOI: 10.1016/J.Jalz.2014.04.005 |
0.422 |
|
| 2014 |
Donohue MC, Sperling RA, Salmon DP, Rentz DM, Raman R, Thomas RG, Weiner M, Aisen PS. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. Jama Neurology. 71: 961-70. PMID 24886908 DOI: 10.1001/Jamaneurol.2014.803 |
0.625 |
|
| 2014 |
Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Galasko D, Schneider LS, Aisen PS. Alzheimer's Disease Cooperative Study Prevention Instrument Project assessing resource use and volunteer and paid work in healthy elders: a longitudinal study. Journal of the American Geriatrics Society. 62: 985-8. PMID 24828933 DOI: 10.1111/Jgs.12816 |
0.418 |
|
| 2014 |
Aisen PS. Serum brain-derived neurotrophic factor and the risk for dementia. Jama. 311: 1684-5. PMID 24756518 DOI: 10.1001/Jama.2014.3120 |
0.376 |
|
| 2014 |
Doody RS, Farlow M, Aisen PS. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. The New England Journal of Medicine. 370: 1460. PMID 24716687 DOI: 10.1056/NEJMc1402193 |
0.394 |
|
| 2014 |
Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, Thomas RG, Aisen PS. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology. 82: 1536-42. PMID 24696507 DOI: 10.1212/Wnl.0000000000000364 |
0.499 |
|
| 2014 |
Donohue MC, Jacqmin-Gadda H, Le Goff M, Thomas RG, Raman R, Gamst AC, Beckett LA, Jack CR, Weiner MW, Dartigues JF, Aisen PS. Estimating long-term multivariate progression from short-term data. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: S400-10. PMID 24656849 DOI: 10.1016/J.Jalz.2013.10.003 |
0.381 |
|
| 2014 |
Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P. The A4 study: stopping AD before symptoms begin? Science Translational Medicine. 6: 228fs13. PMID 24648338 DOI: 10.1126/Scitranslmed.3007941 |
0.631 |
|
| 2014 |
Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. The New England Journal of Medicine. 370: 311-21. PMID 24450890 DOI: 10.1056/Nejmoa1312889 |
0.502 |
|
| 2014 |
Burstein AH, Grimes I, Galasko DR, Aisen PS, Sabbagh M, Mjalli AM. Effect of TTP488 in patients with mild to moderate Alzheimer's disease. Bmc Neurology. 14: 12. PMID 24423155 DOI: 10.1186/1471-2377-14-12 |
0.387 |
|
| 2014 |
Hampel H, Lista S, Teipel SJ, Garaci F, Nisticò R, Blennow K, Zetterberg H, Bertram L, Duyckaerts C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehéricy S, ... ... Aisen PS, et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. Biochemical Pharmacology. 88: 426-49. PMID 24275164 DOI: 10.1016/J.Bcp.2013.11.009 |
0.523 |
|
| 2014 |
Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, Brewer JB, Dale AM, Aisen PS. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 29: 159-65. PMID 24164929 DOI: 10.1177/1533317513507373 |
0.714 |
|
| 2014 |
Swaminathan S, Risacher SL, Yoder KK, West JD, Shen L, Kim S, Inlow M, Foroud T, Jagust WJ, Koeppe RA, Mathis CA, Shaw LM, Trojanowski JQ, Soares H, Aisen PS, et al. Association of plasma and cortical amyloid beta is modulated by APOE ε4 status. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: e9-e18. PMID 23541187 DOI: 10.1016/J.Jalz.2013.01.007 |
0.34 |
|
| 2014 |
Ramanan VK, Risacher SL, Nho K, Kim S, Swaminathan S, Shen L, Foroud TM, Hakonarson H, Huentelman MJ, Aisen PS, Petersen RC, Green RC, Jack CR, Koeppe RA, Jagust WJ, et al. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Molecular Psychiatry. 19: 351-7. PMID 23419831 DOI: 10.1038/Mp.2013.19 |
0.421 |
|
| 2014 |
Sperling R, Mormino E, Schultz A, Rentz D, Aisen P, Johnson K. The Aging Brain - Does Amyloid Matter? Neurobiology of Aging. 35. DOI: 10.1016/J.Neurobiolaging.2014.01.111 |
0.369 |
|
| 2014 |
Grill JD, Raman R, Ernstrom K, Dowsett S, Hake A, Aisen P, Doody R, Cummings J. P4-174: COMPARING RECRUITMENT AMONG GEOGRAPHIC REGIONS IN MULTINATIONAL ALZHEIMER'S DISEASE CLINICAL TRIALS Alzheimer's & Dementia. 10: P852-P853. DOI: 10.1016/J.Jalz.2014.05.1691 |
0.492 |
|
| 2014 |
Henley DB, Dowsett SA, Chen Y, Liu-Seifert H, Grill JD, Doody R, Aisen P, Raman R, Miller DS, Hake AM, Cummings J. P4-101: REGIONAL VARIATION IN ALZHEIMER'S DISEASE PROGRESSION IN A CLINICAL TRIAL SETTING Alzheimer's & Dementia. 10: P821-P821. DOI: 10.1016/J.Jalz.2014.05.1617 |
0.486 |
|
| 2014 |
Ramanan VK, Nho K, Risacher SL, Kim S, Shen L, Swaminathan S, Foroud TM, Aisen P, Hakonarson H, Huentelman M, Jack C, Jagust W, Petersen RC, Potkin S, Shaw L, et al. P3-024: NEXT-GENERATION SEQUENCING OF THE BCHE LOCUS IDENTIFIES A FUNCTIONAL SNP ASSOCIATED WITH ALZHEIMER'S DISEASE BIOMARKERS AND AGE OF ONSET Alzheimer's & Dementia. 10: P636-P636. DOI: 10.1016/J.Jalz.2014.05.1111 |
0.423 |
|
| 2014 |
Nho KT, Kim S, Risacher SL, Shen L, Foroud T, Aisen P, Petersen R, Jack C, Weiner MW, Green R, Toga A, Saykin AJ. P3-019: RARE VARIANT IN PLD3 IS ASSOCIATED WITH ALZHEIMER'S PATTERN OF NEURODEGENERATIVE CHANGES Alzheimer's & Dementia. 10: P634-P634. DOI: 10.1016/J.Jalz.2014.05.1106 |
0.377 |
|
| 2014 |
Nho KT, Kim S, Risacher SL, Shen L, Foroud T, Aisen P, Petersen R, Jack C, Shaw L, Trojanowski JQ, Weiner MW, Green R, Toga A, Saykin AJ. P3-018: INFLUENCE OF RARE PSEN1 VARIANTS ON QUANTITATIVE STRUCTURAL IMAGING AND CSF PHENOTYPES IN LATE ONSET ALZHEIMER'S DISEASE Alzheimer's & Dementia. 10: P633-P633. DOI: 10.1016/J.Jalz.2014.05.1105 |
0.421 |
|
| 2014 |
Nho KT, Kim S, Risacher SL, Shen L, Foroud T, Shaw L, Trojanowski JQ, Aisen P, Petersen R, Jack C, Weiner MW, Green R, Toga A, Saykin AJ. P3-017: ASSOCIATION ANALYSIS OF RARE VARIANTS NEAR THE APOE REGION WITH CEREBROSPINAL FLUID (CSF) BIOMARKERS OF ALZHEIMER'S DISEASE Alzheimer's & Dementia. 10: P632-P633. DOI: 10.1016/J.Jalz.2014.05.1104 |
0.423 |
|
| 2014 |
Liu-Seifert H, Han B, Henley D, Siemers E, Cummings J, Raskin J, Price K, Sundell K, Selzler K, Aisen P, Mohs R. Cognition Impairment Precedes And Predicts Functional Impairment In Mild Alzhiemer’S Disease Alzheimers & Dementia. 10: 203. DOI: 10.1016/J.Jalz.2014.05.1070 |
0.378 |
|
| 2014 |
Risacher SL, Kim S, Nho KT, West JD, Wang Y, Petersen RC, Aisen PS, Jack CR, Jagust WJ, Koeppe R, Weiner MW, Saykin AJ. IC-P-096: INCREASED AMYLOID DEPOSITION IN OLDER ADULTS AT RISK FOR PROGRESSION TO ALZHEIMER'S DISEASE DUE TO GENETIC BACKGROUND AND/OR THE PRESENCE OF SIGNIFICANT MEMORY CONCERNS Alzheimer's & Dementia. 10: P54-P54. DOI: 10.1016/J.Jalz.2014.05.101 |
0.386 |
|
| 2014 |
Weiner MW, Hayes J, Grafman J, Aisen P, Petersen R, Neylan T. F3-03-04: EFFECTS OF TRAUMATIC BRAIN INJURY AND POST-TRAUMATIC STRESS DISORDER ON ALZHEIMER'S DISEASE (AD) IN VETERANS USING ADNI Alzheimer's & Dementia. 10: P205-P205. DOI: 10.1016/J.Jalz.2014.04.260 |
0.391 |
|
| 2014 |
Donohue MC, Gamst A, Jack C, Beckett L, Weiner M, Aisen P, Raman R, Thomas R. Modeling Long-Term Disease Progression With Covariates Alzheimers & Dementia. 10. DOI: 10.1016/J.Jalz.2014.04.253 |
0.309 |
|
| 2014 |
Sano M, Egelko S, Donohue MC, Kaye J, Mundt J, Sun C, Ferris S, Aisen PS. Assessing Clinical Progression For Dementia Prevention Trial: Results From The Hba Trial Alzheimers & Dementia. 10: 138. DOI: 10.1016/J.Jalz.2014.04.084 |
0.403 |
|
| 2013 |
Benzinger TL, Blazey T, Jack CR, Koeppe RA, Su Y, Xiong C, Raichle ME, Snyder AZ, Ances BM, Bateman RJ, Cairns NJ, Fagan AM, Goate A, Marcus DS, Aisen PS, et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 110: E4502-9. PMID 24194552 DOI: 10.1073/Pnas.1317918110 |
0.523 |
|
| 2013 |
Doody RS, Aisen PS, Iwatsubo T. Semagacestat for treatment of Alzheimer's disease. The New England Journal of Medicine. 369: 1661. PMID 24152267 DOI: 10.1056/NEJMc1310845 |
0.387 |
|
| 2013 |
Rizk-Jackson A, Insel P, Petersen R, Aisen P, Jack C, Weiner M. Early indications of future cognitive decline: stable versus declining controls. Plos One. 8: e74062. PMID 24040166 DOI: 10.1371/Journal.Pone.0074062 |
0.367 |
|
| 2013 |
Mills SM, Mallmann J, Santacruz AM, Fuqua A, Carril M, Aisen PS, Althage MC, Belyew S, Benzinger TL, Brooks WS, Buckles VD, Cairns NJ, Clifford D, Danek A, Fagan AM, et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Revue Neurologique. 169: 737-43. PMID 24016464 DOI: 10.1016/J.Neurol.2013.07.017 |
0.543 |
|
| 2013 |
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: e111-94. PMID 23932184 DOI: 10.1016/j.jalz.2013.05.1769 |
0.449 |
|
| 2013 |
Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS, Siemers E, Sethuraman G, Mohs R, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. The New England Journal of Medicine. 369: 341-50. PMID 23883379 DOI: 10.1056/Nejmoa1210951 |
0.446 |
|
| 2013 |
Salmon DP, Ferris SH, Thomas RG, Sano M, Cummings JL, Sperling RA, Petersen RC, Aisen PS. Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly. Neuropsychology. 27: 391-401. PMID 23876113 DOI: 10.1037/A0032707 |
0.591 |
|
| 2013 |
Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, Schneider LS, Weiner M, Doody R, Khachaturian Z, Cedarbaum J, Grundman M, Broich K, Giacobini E, Dubois B, ... ... Aisen P, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: 438-44. PMID 23809364 DOI: 10.1016/J.Jalz.2013.03.007 |
0.607 |
|
| 2013 |
Apostolova LG, Babakchanian S, Hwang KS, Green AE, Zlatev D, Chou YY, DeCarli C, Jack CR, Petersen RC, Aisen PS, Cummings JL, Toga AW, Thompson PM. Ventricular enlargement and its clinical correlates in the imaging cohort from the ADCS MCI donepezil/vitamin E study. Alzheimer Disease and Associated Disorders. 27: 174-81. PMID 23694947 DOI: 10.1097/Wad.0B013E3182677B3D |
0.433 |
|
| 2013 |
Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, Mielke M, Pankratz VS, Roberts R, Rocca WA, Weigand S, Weiner M, Wiste H, Jack CR. Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology. 74: 199-208. PMID 23686697 DOI: 10.1002/Ana.23931 |
0.516 |
|
| 2013 |
Nho K, Corneveaux JJ, Kim S, Lin H, Risacher SL, Shen L, Swaminathan S, Ramanan VK, Liu Y, Foroud T, Inlow MH, Siniard AL, Reiman RA, Aisen PS, Petersen RC, et al. Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Molecular Psychiatry. 18: 781-7. PMID 23608917 DOI: 10.1038/Mp.2013.24 |
0.34 |
|
| 2013 |
Mackin RS, Insel P, Tosun D, Mueller SG, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Lee JY, Jack CR, Aisen PS, Petersen RC, Weiner MW. The effect of subsyndromal symptoms of depression and white matter lesions on disability for individuals with mild cognitive impairment. The American Journal of Geriatric Psychiatry : Official Journal of the American Association For Geriatric Psychiatry. 21: 906-14. PMID 23567388 DOI: 10.1016/J.Jagp.2013.01.021 |
0.391 |
|
| 2013 |
Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, Petersen RC, Jack CR, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ, et al. The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Frontiers in Aging Neuroscience. 5: 11. PMID 23554593 DOI: 10.3389/Fnagi.2013.00011 |
0.44 |
|
| 2013 |
Aisen PS, Vellas B, Hampel H. Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease. Nature Reviews. Drug Discovery. 12: 324. PMID 23493086 DOI: 10.1038/Nrd3842-C1 |
0.47 |
|
| 2013 |
Zhu CW, Sano M, Ferris SH, Whitehouse PJ, Patterson MB, Aisen PS. Health-related resource use and costs in elderly adults with and without mild cognitive impairment. Journal of the American Geriatrics Society. 61: 396-402. PMID 23414481 DOI: 10.1111/Jgs.12132 |
0.322 |
|
| 2013 |
Galasko DR, Aisen P. Antioxidants for Alzheimer disease-reply. Jama Neurology. 70: 270-1. PMID 23400724 DOI: 10.1001/Jamaneurol.2013.935 |
0.49 |
|
| 2013 |
Kantarci K, Gunter JL, Tosakulwong N, Weigand SD, Senjem MS, Petersen RC, Aisen PS, Jagust WJ, Weiner MW, Jack CR. Focal hemosiderin deposits and β-amyloid load in the ADNI cohort. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: S116-23. PMID 23375568 DOI: 10.1016/J.Jalz.2012.10.011 |
0.483 |
|
| 2013 |
Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. The Lancet. Neurology. 12: 207-16. PMID 23332364 DOI: 10.1016/S1474-4422(12)70291-0 |
0.51 |
|
| 2013 |
Aisen PS, Vellas B. Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed? The Journal of Nutrition, Health & Aging. 17: 49-50. PMID 23299379 DOI: 10.1007/S12603-013-0001-3 |
0.412 |
|
| 2013 |
Grill JD, Raman R, Ernstrom K, Aisen P, Karlawish J. Effect of study partner on the conduct of Alzheimer disease clinical trials. Neurology. 80: 282-8. PMID 23255824 DOI: 10.1212/Wnl.0B013E31827Debfe |
0.512 |
|
| 2013 |
Sano M, Egelko S, Donohue M, Ferris S, Kaye J, Hayes TL, Mundt JC, Sun CK, Paparello S, Aisen PS. Developing dementia prevention trials: baseline report of the Home-Based Assessment study. Alzheimer Disease and Associated Disorders. 27: 356-62. PMID 23151596 DOI: 10.1097/Wad.0B013E3182769C05 |
0.364 |
|
| 2013 |
Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM. Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease. Ajnr. American Journal of Neuroradiology. 34: 505-10. PMID 22976236 DOI: 10.3174/Ajnr.A3267 |
0.564 |
|
| 2013 |
Mills S, Mallmann J, Santacruz A, Fuqua A, Carril M, Aisen P, Althage M, Belyew S, Benzinger T, Brooks W, Buckles V, Cairns N, Clifford D, Danek A, Fagan A, et al. Erratum to “Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial” [Rev. Neurol. 169 (10) (2013) 737–743] Revue Neurologique. 169: 1018. DOI: 10.1016/J.Neurol.2013.10.005 |
0.499 |
|
| 2013 |
Rissman RA, Donohue M, Moghadam S, Sun C, Roe A, Edland S, Aisen P. Factors that influence use of plasma beta-amyloid as a biomarker of Alzheimer's disease Alzheimers & Dementia. 9. DOI: 10.1016/J.Jalz.2013.08.189 |
0.421 |
|
| 2013 |
Turner R, Craft S, Aisen P. Individuals with Alzheimer's disease exhibit a high prevalence of undiagnosed impaired glucose tolerance and type 2 diabetes mellitus Alzheimers & Dementia. 9. DOI: 10.1016/J.Jalz.2013.05.573 |
0.347 |
|
| 2013 |
Langbaum J, High N, Aisen P, Albert M, Brown K, Comer M, Cummings J, Manly J, Petersen R, Sperling R, Strobel G, Weiner M, Tariot P, Reiman E. Development and implementation of the National Alzheimer's Prevention Registry Alzheimers & Dementia. 9: 280. DOI: 10.1016/J.Jalz.2013.05.560 |
0.553 |
|
| 2013 |
Nosheny R, Insel P, Truran D, Schuff N, Jack C, Aisen P, Petersen R, Jagust W, Shaw L, Trojanowski J, Weiner M. P1-158: The effect of age and amyloid status on hippocampal atrophy rate in normal controls and people with mild cognitive impairment in the ADNI cohort Alzheimer's & Dementia. 9: P207-P207. DOI: 10.1016/J.Jalz.2013.05.381 |
0.376 |
|
| 2013 |
Sano M, Egelko S, Donohue M, Paparello S, Ferris S, Kaye J, Hayes TL, Mundt J, Sun C, Aisen P. Satisfaction of elderly research volunteers with home-based clinical trial participation Alzheimers & Dementia. 9: 781. DOI: 10.1016/J.Jalz.2013.05.1597 |
0.314 |
|
| 2013 |
Risacher S, Petersen R, Aisen P, Jack C, Koeppe R, Jagust W, Farias ST, Mungas D, Trojanowski J, Shaw L, Weiner M, Saykin A. IC-P-105: Self-reported versus informant-based cognitive complaints: Relation of E-Cog scores to imaging biomarkers and clinical status in ADNI-2 Alzheimer's & Dementia. 9: P60-P62. DOI: 10.1016/J.Jalz.2013.05.102 |
0.31 |
|
| 2013 |
Jack C, Knopman D, Jagust W, Petersen R, Weiner M, Aisen P, Shaw L, Vemuri P, Wiste H, Weigand S, Lesnick T, Pankratz V, Donohue M, Trojanowski J. O3-03-01: Update on hypothetical model of Alzheimer's disease biomarkers Alzheimer's & Dementia. 9: P521-P522. DOI: 10.1016/J.Jalz.2013.04.248 |
0.425 |
|
| 2012 |
Morris JC, Aisen PS, Bateman RJ, Benzinger TL, Cairns NJ, Fagan AM, Ghetti B, Goate AM, Holtzman DM, Klunk WE, McDade E, Marcus DS, Martins RN, Masters CL, Mayeux R, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clinical Investigation. 2: 975-984. PMID 23139856 DOI: 10.4155/Cli.12.93 |
0.592 |
|
| 2012 |
Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, Weiner MW, Jagust WJ. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Annals of Neurology. 72: 578-86. PMID 23109153 DOI: 10.1002/Ana.23650 |
0.467 |
|
| 2012 |
Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. Down's syndrome and Alzheimer's disease: Towards secondary prevention Nature Reviews Drug Discovery. 11: 655-656. PMID 22935789 DOI: 10.1038/Nrd3822 |
0.703 |
|
| 2012 |
Ramanan VK, Kim S, Holohan K, Shen L, Nho K, Risacher SL, Foroud TM, Mukherjee S, Crane PK, Aisen PS, Petersen RC, Weiner MW, Saykin AJ. Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging and Behavior. 6: 634-48. PMID 22865056 DOI: 10.1007/S11682-012-9196-X |
0.353 |
|
| 2012 |
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, ... Aisen PS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. The New England Journal of Medicine. 367: 795-804. PMID 22784036 DOI: 10.1056/Nejmoa1202753 |
0.598 |
|
| 2012 |
Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, Friedrich S, Dean RA, Gonzales C, Sethuraman G, DeMattos RB, Mohs R, Paul SM, Siemers ER. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: 261-71. PMID 22672770 DOI: 10.1016/J.Jalz.2011.09.224 |
0.434 |
|
| 2012 |
Reiman EM, Brinton RD, Katz R, Petersen RC, Negash S, Mungas D, Aisen PS. Considerations in the design of clinical trials for cognitive aging. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 67: 766-72. PMID 22573913 DOI: 10.1093/Gerona/Gls124 |
0.392 |
|
| 2012 |
Desikan RS, McEvoy LK, Thompson WK, Holland D, Brewer JB, Aisen PS, Sperling RA, Dale AM. Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. Archives of Neurology. 69: 709-13. PMID 22529247 DOI: 10.1001/Archneurol.2011.3354 |
0.603 |
|
| 2012 |
Donohue MC, Aisen PS. Mixed model of repeated measures versus slope models in alzheimer's disease clinical trials Journal of Nutrition, Health and Aging. 16: 360-364. PMID 22499459 DOI: 10.1007/S12603-012-0047-7 |
0.474 |
|
| 2012 |
Vellas B, Hampel H, Rougé-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, Bateman R, Berman R, Black R, Carrillo M, Donohue M, Mintun M, Morris J, Petersen R, Thomas RG, ... ... Aisen P, et al. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology. The Journal of Nutrition, Health & Aging. 16: 339-45. PMID 22499454 DOI: 10.1007/S12603-012-0044-X |
0.508 |
|
| 2012 |
Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P. Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Archives of Neurology. 69: 836-41. PMID 22431837 DOI: 10.1001/Archneurol.2012.85 |
0.444 |
|
| 2012 |
Bernick C, Cummings J, Raman R, Sun X, Aisen P. Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Archives of Neurology. 69: 901-5. PMID 22431834 DOI: 10.1001/Archneurol.2011.3758 |
0.541 |
|
| 2012 |
Irizarry MC, Jin S, He F, Emond JA, Raman R, Thomas RG, Sano M, Quinn JF, Tariot PN, Galasko DR, Ishihara LS, Weil JG, Aisen PS. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Archives of Neurology. 69: 368-72. PMID 22410444 DOI: 10.1001/Archneurol.2011.830 |
0.431 |
|
| 2012 |
Jack CR, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, Kantarci K, Bernstein MA, Senjem ML, Gunter JL, Boeve BF, Trojanowski JQ, Shaw LM, Aisen PS, Weiner MW, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Archives of Neurology. 69: 856-67. PMID 22409939 DOI: 10.1001/Archneurol.2011.3405 |
0.453 |
|
| 2012 |
Aisen PS, Cummings J, Schneider LS. Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 2: a006395. PMID 22393531 DOI: 10.1101/Cshperspect.A006395 |
0.499 |
|
| 2012 |
Tractenberg RE, Yumoto F, Aisen PS, Kaye JA, Mislevy RJ. Using the Guttman scale to define and estimate measurement error in items over time: the case of cognitive decline and the meaning of "points lost". Plos One. 7: e30019. PMID 22363411 DOI: 10.1371/Journal.Pone.0030019 |
0.325 |
|
| 2012 |
Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 119: 843-50. PMID 22354745 DOI: 10.1007/S00702-012-0772-4 |
0.71 |
|
| 2012 |
Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 8: S1-68. PMID 22047634 DOI: 10.1016/J.Jalz.2011.09.172 |
0.54 |
|
| 2012 |
Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JQ, Aisen P, Petersen RC, Schuff N, Weiner MW. CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cerebral Cortex (New York, N.Y. : 1991). 22: 1993-2004. PMID 22038908 DOI: 10.1093/Cercor/Bhr271 |
0.403 |
|
| 2012 |
Mackin RS, Insel P, Aisen PS, Geda YE, Weiner MW. Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years. International Journal of Geriatric Psychiatry. 27: 355-63. PMID 21744390 DOI: 10.1002/Gps.2713 |
0.336 |
|
| 2012 |
Schuff N, Tosun D, Insel PS, Chiang GC, Truran D, Aisen PS, Jack CR, Weiner MW. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiology of Aging. 33: 845-55. PMID 20855131 DOI: 10.1016/J.Neurobiolaging.2010.07.012 |
0.451 |
|
| 2012 |
Farias S, Saito N, Harvey D, Aisen P, Petersen R. The Validity of Self-Reported Functional Decline Varies by Disease Severity (P04.205) Neurology. 78. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P04.205 |
0.417 |
|
| 2012 |
Sperling R, Downing AC, Salmon D, Rentz D, Siemers E, Sethuraman G, Karlawish J, Johnson K, Donohue M, Aisen P. The A4 trial: Anti-amyloid treatment of asymptomatic Alzheimer's disease Alzheimers & Dementia. 10: 246. DOI: 10.1016/J.Jalz.2014.04.378 |
0.596 |
|
| 2012 |
Ramanan V, Kim S, Holohan K, Shen L, Ngo K, Risacher S, Foroud T, Mukherjee S, Crane P, Aisen P, Petersen R, Weiner M, Saykin A. Common gene networks underlying memory impairment: A comparison of pathway analysis methods in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort Alzheimers & Dementia. 8. DOI: 10.1016/J.Jalz.2012.05.1844 |
0.389 |
|
| 2012 |
Donohue M, Aisen P, Dartigues J, Jacqmin-Gadda H, Gamst A, Goff ML. Validating Alzheimer's pathological cascade by merging ADNI with PAQUID Alzheimers & Dementia. 8. DOI: 10.1016/J.Jalz.2012.05.1636 |
0.48 |
|
| 2012 |
Li T, Yan J, Kim S, Swaminathan S, Risacher S, Shaw L, Trojanowski J, Aisen P, Petersen R, Weiner M, Saykin A, Shen L. O4-01-01: Classification of MCI and Alzheimer's disease from CSF biomarkers: An ADNI study of Aß, tau and P-tau versus 83 proteomic analytes Alzheimer's & Dementia. 8: P609-P610. DOI: 10.1016/J.Jalz.2012.05.1634 |
0.454 |
|
| 2012 |
Aisen P, Thomas R, Carrillo M, Mohs R, Petersen R, Siuciak J, Albert M. The Placebo Data Analysis in Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) Clinical Trials Project: Overview of progress in trial data collection, and key findings from the pooled Alzheimer's disease trial datasets Alzheimers & Dementia. 8: 590. DOI: 10.1016/J.Jalz.2012.05.1609 |
0.384 |
|
| 2012 |
Grill J, Raman R, Ernstrom K, Aisen P, Karlawish J. P3-369: Alzheimer's disease patients with adult child study partners are underrepresented in clinical trials and may experience slower cognitive decline Alzheimer's & Dementia. 8: P585-P586. DOI: 10.1016/J.Jalz.2012.05.1594 |
0.484 |
|
| 2012 |
Quinn J, Shinto L, Yurko-Mauro K, Galasko D, Aisen P, Montine T. P3-368: Biomarkers of fatty acid oxidation in a clinical trial of DHA for Alzheimer's disease Alzheimer's & Dementia. 8: P585-P585. DOI: 10.1016/J.Jalz.2012.05.1593 |
0.44 |
|
| 2012 |
Risacher S, Kim S, Shen L, Ngo K, Foroud T, Petersen R, Aisen P, Jack C, Koeppe R, Jagust W, Weiner M, Saykin A. IC-P-098: The role of APOE-ɛ4 genotype in early mild cognitive impairment (EMCI): Preliminary results from ADNI-2 Alzheimer's & Dementia. 8: P56-P57. DOI: 10.1016/J.Jalz.2012.05.131 |
0.311 |
|
| 2012 |
Doody R, Winblad B, Cummings J, Tariot P, Sano M, Aisen P, Selby B, Seely L. Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials Alzheimers & Dementia. 8: 456. DOI: 10.1016/J.Jalz.2012.05.1217 |
0.522 |
|
| 2012 |
Relkin N, Gessert D, Stokes K, Adamiak B, Ngo LY, Thomas R, Gelmont D, Aisen P. The Gammaglobulin Alzheimer Partnership Study (GAP): Design, screening, enrollment and futility analysis results Alzheimers & Dementia. 8: 456. DOI: 10.1016/J.Jalz.2012.05.1216 |
0.342 |
|
| 2011 |
Hu X, Pickering EH, Hall SK, Naik S, Liu YC, Soares H, Katz E, Paciga SA, Liu W, Aisen PS, Bales KR, Samad TA, John SL. Genome-wide association study identifies multiple novel loci associated with disease progression in subjects with mild Cognitive impairment Translational Psychiatry. 1. PMID 22833209 DOI: 10.1038/Tp.2011.50 |
0.359 |
|
| 2011 |
Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, Duong A, Suhy J, Oh J, Lau WC, Sampalis J. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Archives of Medical Science : Ams. 7: 102-11. PMID 22291741 DOI: 10.5114/Aoms.2011.20612 |
0.542 |
|
| 2011 |
Sperling RA, Jack CR, Aisen PS. Testing the right target and right drug at the right stage. Science Translational Medicine. 3: 111cm33. PMID 22133718 DOI: 10.1126/Scitranslmed.3002609 |
0.596 |
|
| 2011 |
Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM. Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Annals of Neurology. 70: 657-61. PMID 22002658 DOI: 10.1002/Ana.22509 |
0.423 |
|
| 2011 |
Aisen PS. Clinical trial methodologies for disease-modifying therapeutic approaches. Neurobiology of Aging. 32: S64-6. PMID 21983242 DOI: 10.1016/J.Neurobiolaging.2011.09.008 |
0.534 |
|
| 2011 |
Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, et al. Prevention trials in Alzheimer's disease: an EU-US task force report. Progress in Neurobiology. 95: 594-600. PMID 21925234 DOI: 10.1016/J.Pneurobio.2011.08.014 |
0.537 |
|
| 2011 |
Fleisher AS, Truran D, Mai JT, Langbaum JB, Aisen PS, Cummings JL, Jack CR, Weiner MW, Thomas RG, Schneider LS, Tariot PN. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 77: 1263-71. PMID 21917762 DOI: 10.1212/Wnl.0B013E318230A16C |
0.479 |
|
| 2011 |
Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, et al. Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 514-20. PMID 21889115 DOI: 10.1016/J.Jalz.2010.12.010 |
0.46 |
|
| 2011 |
Aisen PS. Q&A: The Alzheimer's Disease Neuroimaging Initiative. Bmc Medicine. 9: 101. PMID 21884605 DOI: 10.1186/1741-7015-9-101 |
0.475 |
|
| 2011 |
Jack CR, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS. Evidence for ordering of Alzheimer disease biomarkers. Archives of Neurology. 68: 1526-35. PMID 21825215 DOI: 10.1001/Archneurol.2011.183 |
0.47 |
|
| 2011 |
Tariot PN, Schneider LS, Cummings J, Thomas RG, Raman R, Jakimovich LJ, Loy R, Bartocci B, Fleisher A, Ismail MS, Porsteinsson A, Weiner M, Jack CR, Thal L, Aisen PS, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Archives of General Psychiatry. 68: 853-61. PMID 21810649 DOI: 10.1001/Archgenpsychiatry.2011.72 |
0.485 |
|
| 2011 |
Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, Jack CR, Jagust W, Decarli C, Toga AW, Toledo E, Xie SX, Lee VM, Trojanowski JQ, Shaw LM, et al. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathologica. 122: 401-13. PMID 21805181 DOI: 10.1007/S00401-011-0861-8 |
0.394 |
|
| 2011 |
Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, Aisen PS. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 77: 556-63. PMID 21795660 DOI: 10.1212/Wnl.0B013E318228Bf11 |
0.519 |
|
| 2011 |
Vellas B, Pesce A, Robert PH, Aisen PS, Ancoli-Israel S, Andrieu S, Cedarbaum J, Dubois B, Siemers E, Spire JP, Weiner MW, May TS. AMPA workshop on challenges faced by investigators conducting Alzheimer's disease clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: e109-17. PMID 21784343 DOI: 10.1016/J.Jalz.2010.05.2020 |
0.475 |
|
| 2011 |
Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, Weiner MW, Jagust WJ. Longitudinal change of biomarkers in cognitive decline. Archives of Neurology. 68: 1257-66. PMID 21670386 DOI: 10.1001/Archneurol.2011.123 |
0.461 |
|
| 2011 |
Aisen PS. Commentary on "Biomarkers in Alzheimer's disease drug development." Can't live without 'em. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: e48-50. PMID 21575868 DOI: 10.1016/J.Jalz.2010.06.006 |
0.532 |
|
| 2011 |
Donohue MC, Gamst AC, Thomas RG, Xu R, Beckett L, Petersen RC, Weiner MW, Aisen P. The relative efficiency of time-to-threshold and rate of change in longitudinal data. Contemporary Clinical Trials. 32: 685-93. PMID 21554992 DOI: 10.1016/J.Cct.2011.04.007 |
0.318 |
|
| 2011 |
Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 280-92. PMID 21514248 DOI: 10.1016/J.Jalz.2011.03.003 |
0.66 |
|
| 2011 |
Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 76: 1389-94. PMID 21502597 DOI: 10.1212/Wnl.0B013E318216Eb7B |
0.714 |
|
| 2011 |
Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE, Trojanowski JQ, Shaw LM, Decarli CS, Carmichael O, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain : a Journal of Neurology. 134: 1479-92. PMID 21478184 DOI: 10.1093/Brain/Awr049 |
0.447 |
|
| 2011 |
Donohue MC, Gamst AC, Aisen PS. Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 245-6; author reply . PMID 21414558 DOI: 10.1016/J.Jalz.2010.12.013 |
0.524 |
|
| 2011 |
Khachaturian ZS, Petersen RC, Snyder PJ, Khachaturian AS, Aisen P, de Leon M, Greenberg BD, Kukull W, Maruff P, Sperling RA, Stern Y, Touchon J, Vellas B, Andrieu S, Weiner MW, et al. Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 7: 127-32. PMID 21414553 DOI: 10.1016/J.Jalz.2011.02.005 |
0.521 |
|
| 2011 |
Rammouz G, Lecanu L, Aisen P, Papadopoulos V. A lead study on oxidative stress-mediated dehydroepiandrosterone formation in serum: the biochemical basis for a diagnosis of Alzheimer's disease. Journal of Alzheimer's Disease : Jad. 24: 5-16. PMID 21335661 DOI: 10.3233/Jad-2011-101941 |
0.433 |
|
| 2011 |
Niikura T, Sidahmed E, Hirata-Fukae C, Aisen PS, Matsuoka Y. A humanin derivative reduces amyloid beta accumulation and ameliorates memory deficit in triple transgenic mice. Plos One. 6: e16259. PMID 21264226 DOI: 10.1371/Journal.Pone.0016259 |
0.383 |
|
| 2011 |
Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer's Research & Therapy. 3: 1. PMID 21211070 DOI: 10.1186/Alzrt59 |
0.644 |
|
| 2011 |
Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, Galasko D. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease Alzheimer Disease and Associated Disorders. 25: 206-212. PMID 21192237 DOI: 10.1097/Wad.0B013E318204B550 |
0.377 |
|
| 2011 |
Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, Feldman HH, Petersen RC, Siemers E, Doody RS, Hendrix SB, Grundman M, Schneider LS, Schindler RJ, Salmon E, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology. 76: 280-6. PMID 21178097 DOI: 10.1212/Wnl.0B013E318207B1B9 |
0.403 |
|
| 2011 |
Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, et al. Biomarkers for Alzheimer's disease therapeutic trials. Progress in Neurobiology. 95: 579-93. PMID 21130138 DOI: 10.1016/J.Pneurobio.2010.11.005 |
0.547 |
|
| 2011 |
Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, et al. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology. 76: 69-79. PMID 21123754 DOI: 10.1212/Wnl.0B013E318204A397 |
0.359 |
|
| 2011 |
Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS. Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease. Alzheimer Disease and Associated Disorders. 25: 122-7. PMID 20921876 DOI: 10.1097/Wad.0B013E3181F883B7 |
0.54 |
|
| 2011 |
Schafer K, Sano M, Aisen P, Donohue M, Sun C, Schneider L. P1-472: Extent and impact of missing ADAS-cog items in ADCS clinical trials Alzheimer's & Dementia. 7: S264-S264. DOI: 10.1016/J.Jalz.2011.05.754 |
0.321 |
|
| 2011 |
Schuff N, Insel P, Chiang G, Truran D, Gamst A, Jack C, Aisen P, Petersen R, Shaw L, Trojanowski J, Weiner M. Acceleration of brain atrophy rates with advancing cognitive deterioration from normal aging to MCI to Alzheimer's disease Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.626 |
0.363 |
|
| 2011 |
Chao L, Schuff N, Aisen P, Petersen R, Jack C, Weiner M. Callosal atrophy in mild cognitive impairment and Alzheimer's disease Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.582 |
0.491 |
|
| 2011 |
Sano M, Egelko S, Ferris S, Kaye J, Hayes T, Mundt J, Reyes T, Donohue M, Sun C, Whitehair D, Stokes K, Aisen P. Alzheimer disease cooperative study (ADCS) home based assessment: Designing trials with new technology Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.1434 |
0.425 |
|
| 2011 |
Landau S, Petersen R, Aisen P, Jagust W. IC-P-049: Change in amyloid deposition is related to concurrent cognitive change in MCI Alzheimer's & Dementia. 7: S28-S28. DOI: 10.1016/J.Jalz.2011.05.118 |
0.348 |
|
| 2011 |
Jack C, Vemuri P, Wiste H, Weigand S, Aisen P, Trojanowski J, Shaw L, Bernstein M, Petersen R, Weiner M, Knopman D. IC-02-04: Ordering of Alzheimer's disease biomarkers Alzheimer's & Dementia. 7: S4-S5. DOI: 10.1016/J.Jalz.2011.05.011 |
0.422 |
|
| 2011 |
Quinn JF, Aisen PS. Docosahexaenoic Acid Supplementation and Alzheimer Disease—Reply Jama. 305: 672-673. DOI: 10.1001/Jama.2011.141 |
0.356 |
|
| 2010 |
Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR, Weiner M, Shinto L, Aisen PS. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. Jama. 304: 1903-11. PMID 21045096 DOI: 10.1001/Jama.2010.1510 |
0.442 |
|
| 2010 |
McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan JM, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Y. Dependence as a unifying construct in defining Alzheimer's disease severity. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 482-93. PMID 21044778 DOI: 10.1016/J.Jalz.2009.09.004 |
0.495 |
|
| 2010 |
Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Jack CR, Aisen PS, Petersen RC, Weiner MW. Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology. 75: 1976-81. PMID 20980669 DOI: 10.1212/Wnl.0B013E3181Ffe4D1 |
0.439 |
|
| 2010 |
Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Zeng G, Bernstein MA, Gunter JL, Pankratz VS, Aisen PS, Weiner MW, Petersen RC, Shaw LM, Trojanowski JQ, Knopman DS, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain : a Journal of Neurology. 133: 3336-48. PMID 20935035 DOI: 10.1093/Brain/Awq277 |
0.476 |
|
| 2010 |
Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 412-9. PMID 20813342 DOI: 10.1016/J.Jalz.2009.12.003 |
0.436 |
|
| 2010 |
McEvoy LK, Edland SD, Holland D, Hagler DJ, Roddey JC, Fennema-Notestine C, Salmon DP, Koyama AK, Aisen PS, Brewer JB, Dale AM. Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease. Alzheimer Disease and Associated Disorders. 24: 269-77. PMID 20683184 DOI: 10.1097/Wad.0B013E3181D1B814 |
0.474 |
|
| 2010 |
Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR. Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology. 75: 143-51. PMID 20625167 DOI: 10.1212/Wnl.0B013E3181E7Ca82 |
0.486 |
|
| 2010 |
Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR, Weiner MW, Jagust WJ. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 75: 230-8. PMID 20592257 DOI: 10.1212/Wnl.0B013E3181E8E8B8 |
0.491 |
|
| 2010 |
Tractenberg RE, Fillenbaum G, Aisen PS, Liebke DE, Yumoto F, Kuchibhatla MN. What the CERAD Battery Can Tell Us about Executive Function as a Higher-Order Cognitive Faculty. Current Gerontology and Geriatrics Research. 510614. PMID 20585350 DOI: 10.1155/2010/510614 |
0.311 |
|
| 2010 |
Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study. Neurobiology of Aging. 31: 1340-54. PMID 20570401 DOI: 10.1016/J.Neurobiolaging.2010.04.030 |
0.467 |
|
| 2010 |
Apostolova LG, Hwang KS, Andrawis JP, Green AE, Babakchanian S, Morra JH, Cummings JL, Toga AW, Trojanowski JQ, Shaw LM, Jack CR, Petersen RC, Aisen PS, Jagust WJ, Koeppe RA, et al. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiology of Aging. 31: 1284-303. PMID 20538372 DOI: 10.1016/J.Neurobiolaging.2010.05.003 |
0.35 |
|
| 2010 |
Edland SD, Emond JA, Aisen PS, Petersen RC. NIA-funded Alzheimer centers are more efficient than commercial clinical recruitment sites for conducting secondary prevention trials of dementia. Alzheimer Disease and Associated Disorders. 24: 159-64. PMID 20505433 DOI: 10.1097/Wad.0B013E3181C9983F |
0.454 |
|
| 2010 |
Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, Shaw LM, Beckett LA, Jack CR, Jagust W, Toga AW, Saykin AJ, Morris JC, et al. Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 239-46. PMID 20451872 DOI: 10.1016/J.Jalz.2010.03.006 |
0.537 |
|
| 2010 |
Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter WZ, Weiner MW, Jack CR, et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 230-8. PMID 20451871 DOI: 10.1016/J.Jalz.2010.03.008 |
0.533 |
|
| 2010 |
Weiner MW, Aisen PS, Jack CR, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, et al. The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 202-11.e7. PMID 20451868 DOI: 10.1016/J.Jalz.2010.03.007 |
0.515 |
|
| 2010 |
Shineman DW, Salthouse TA, Launer LJ, Hof PR, Bartzokis G, Kleiman R, Luine V, Buccafusco JJ, Small GW, Aisen PS, Lowe DA, Fillit HM. Therapeutics for cognitive aging. Annals of the New York Academy of Sciences. 1191: E1-15. PMID 20392284 DOI: 10.1111/J.1749-6632.2010.05532.X |
0.384 |
|
| 2010 |
Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Shaw LM, Trojanowski JQ, Aisen PS, Weiner M, Petersen RC, Jack CR. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Annals of Neurology. 67: 308-16. PMID 20373342 DOI: 10.1002/Ana.21953 |
0.484 |
|
| 2010 |
Aisen PS. Pre-dementia Alzheimer's trials: overview. Journal of Nutrition Health & Aging. 14: 294-294. PMID 20305998 DOI: 10.1007/S12603-010-0065-2 |
0.513 |
|
| 2010 |
Vellas B, Aisen PS. Early Alzheimer's trials: new developments. The Journal of Nutrition, Health & Aging. 14: 293. PMID 20305997 DOI: 10.1007/S12603-010-0064-3 |
0.457 |
|
| 2010 |
Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, Sager MA, Shankle WR, Snyder PJ, Petersen RC, Schellenberg G, Trojanowski J, Aisen P, Albert MS, Breitner JC, et al. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 6: 89-97. PMID 20298968 DOI: 10.1016/J.Jalz.2010.01.008 |
0.464 |
|
| 2010 |
Apostolova LG, Thompson PM, Green AE, Hwang KS, Zoumalan C, Jack CR, Harvey DJ, Petersen RC, Thal LJ, Aisen PS, Toga AW, Cummings JL, Decarli CS. 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI. Human Brain Mapping. 31: 786-97. PMID 20143386 DOI: 10.1002/Hbm.20905 |
0.399 |
|
| 2010 |
Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. The Lancet. Neurology. 9: 119-28. PMID 20083042 DOI: 10.1016/S1474-4422(09)70299-6 |
0.485 |
|
| 2010 |
Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, Jack CR, Jagust WJ, Shaw LM, Toga AW, Trojanowski JQ, Weiner MW. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 74: 201-9. PMID 20042704 DOI: 10.1212/Wnl.0B013E3181Cb3E25 |
0.467 |
|
| 2010 |
Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K. Biological markers of amyloid beta-related mechanisms in Alzheimer's disease. Experimental Neurology. 223: 334-46. PMID 19815015 DOI: 10.1016/J.Expneurol.2009.09.024 |
0.469 |
|
| 2010 |
Fleisher AS, Jack CR, Weiner MW, Truran D, Mai J, Aisen PS, Cummings JL, Thomas RG, Schneider LS, Tariot PN. Brain volume changes with divalproex sodium in Alzheimer's disease Alzheimer's & Dementia. 6: S302-S303. DOI: 10.1016/J.Jalz.2010.05.988 |
0.429 |
|
| 2010 |
Landau SM, Harvey D, Reiman EM, Foster NL, Aisen PS, Trojanowski JQ, Shaw L, Jack CR, Petersen RC, Weiner MW, Jagust WJ. O3-03-08: Biomarker predictors of cognitive decline in healthy older participants in the Alzheimer's Disease Neuroimaging Initiative Alzheimer's & Dementia. 6: S131-S131. DOI: 10.1016/J.Jalz.2010.05.411 |
0.461 |
|
| 2010 |
Donohue M, Gamst A, Thomas R, Brewer J, Weiner M, Aisen P. Rate of decline in ADNI normal controls with evidence of amyloid burden Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.395 |
0.34 |
|
| 2010 |
Jack CR, Wiste HJ, Vemuri P, Weigand SD, Senjem ML, Knopman DS, Bernstein MA, Gunter JL, Aisen PS, Weiner MW, Petersen RC, Jagust WJ, Shaw LM, Trojanowski JQ. Brain Aβ amyloid measures and MRI are complimentary predictors of progression from MCI to Alzheimer's disease Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.307 |
0.507 |
|
| 2010 |
Jack CR, Weigand SD, Vemuri P, Wiste HJ, Aisen PS, Petersen RC, Weiner MW, Knopman DS, Shaw LM, Trojanowski JQ. O1-02-08: Transforming CSF Aβ42 measures of brain beta-amyloid into calculated PIB (PIBcalc) units Alzheimer's & Dementia. 6: S72-S73. DOI: 10.1016/J.Jalz.2010.05.216 |
0.313 |
|
| 2010 |
Aisen PS. Predictors of progression in the ADNI-MCI cohort Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.180 |
0.394 |
|
| 2010 |
Vemuri P, Wiste HJ, Weigand SD, Knopman DS, Trojanowski JQ, Shaw LM, Bernstein MA, Aisen PS, Weiner M, Petersen RC, Jack CR. Serial MRI and CSF biomarkers in normal aging, MCI and Alzheimer's disease Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.1678 |
0.468 |
|
| 2010 |
Petersen RC, Gill DP, Phillips LE, Aisen P. Early MCI as an imaging target: Data from the National Alzheimer's Coordinating Center Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.163 |
0.381 |
|
| 2010 |
Quinn JF, Thomas R, Raman R, Yurko-Mauro K, Bailey-Hall E, Nelson E, Shaw L, Aisen P. Cerebrospinal fluid biomarker outcomes in a trial of docosahexaenoic acid (DHA) for Alzheimer's disease Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.1002 |
0.446 |
|
| 2009 |
Fleisher AS, Donohue M, Chen K, Brewer JB, Aisen PS. Applications of neuroimaging to disease-modification trials in Alzheimer's disease. Behavioural Neurology. 21: 129-36. PMID 19847051 DOI: 10.3233/Ben-2009-0241 |
0.561 |
|
| 2009 |
Aisen PS. Alzheimer's disease therapeutic research: the path forward. Alzheimer's Research & Therapy. 1: 2-2. PMID 19674435 DOI: 10.1186/Alzrt2 |
0.479 |
|
| 2009 |
Tariot PN, Aisen PS. Can lithium or valproate untie tangles in Alzheimer's disease? The Journal of Clinical Psychiatry. 70: 919-921. PMID 19573485 DOI: 10.4088/Jcp.09Com05331 |
0.509 |
|
| 2009 |
Raman R, Thomas RG, Weiner MW, Jack CR, Ernstrom K, Aisen PS, Tariot PN, Quinn JF. MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population. Alzheimer Disease and Associated Disorders. 23: 333-6. PMID 19571733 DOI: 10.1097/Wad.0B013E3181Aba588 |
0.503 |
|
| 2009 |
Matsuoka Y, Andrews HF, Becker AG, Gray AJ, Mehta PD, Sano MC, Dalton AJ, Aisen PS. The relationship of plasma Abeta levels to dementia in aging individuals with Down syndrome. Alzheimer Disease and Associated Disorders. 23: 315-8. PMID 19571732 DOI: 10.1097/Wad.0B013E3181Aba61E |
0.381 |
|
| 2009 |
Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, Garceau D, Suhy J, Oh J, Lau W, Sampalis J. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. The Journal of Nutrition, Health & Aging. 13: 550-7. PMID 19536424 DOI: 10.1007/S12603-009-0106-X |
0.5 |
|
| 2009 |
Vozdolska R, Sano M, Aisen P, Edland SD. The net effect of alternative allocation ratios on recruitment time and trial cost. Clinical Trials (London, England). 6: 126-32. PMID 19342464 DOI: 10.1177/1740774509103485 |
0.305 |
|
| 2009 |
Aisen PS. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Facilitating Alzheimer's disease drug development in the United States. Alzheimers & Dementia. 5: 125-127. PMID 19328440 DOI: 10.1016/J.Jalz.2009.01.005 |
0.535 |
|
| 2009 |
Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, et al. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 5: 85-92. PMID 19328434 DOI: 10.1016/j.jalz.2009.01.021 |
0.31 |
|
| 2009 |
Saumier D, Aisen PS, Gauthier S, Vellas B, Ferris SH, Duong A, Suhy J, Oh J, Lau W, Garceau D, Haine D, Sampalis J. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the ALZHEMED (Tramiprosate) experience. The Journal of Nutrition, Health & Aging. 13: 370-2. PMID 19300884 DOI: 10.1007/S12603-009-0047-4 |
0.442 |
|
| 2009 |
Aisen PS. Interpreting Biomarker Data In Therapeutic Trials Journal of Nutrition Health & Aging. 13: 337-338. PMID 19300871 DOI: 10.1007/S12603-009-0034-9 |
0.463 |
|
| 2009 |
Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Annals of Neurology. 65: 403-13. PMID 19296504 DOI: 10.1002/Ana.21610 |
0.493 |
|
| 2009 |
Tractenberg RE, Aisen PS. Agreement in cognitive and clinical assessments in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 27: 344-52. PMID 19293567 DOI: 10.1159/000209212 |
0.421 |
|
| 2009 |
Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. Bmc Medicine. 7: 7. PMID 19228370 DOI: 10.1186/1741-7015-7-7 |
0.737 |
|
| 2009 |
Andrieu S, Coley N, Aisen P, Carrillo MC, DeKosky S, Durga J, Fillit H, Frisoni GB, Froelich L, Gauthier S, Jones R, Jönsson L, Khachaturian Z, Morris JC, Orgogozo JM, et al. Methodological issues in primary prevention trials for neurodegenerative dementia. Journal of Alzheimer's Disease : Jad. 16: 235-70. PMID 19221415 DOI: 10.3233/Jad-2009-0971 |
0.459 |
|
| 2009 |
Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS. Plasma urate and progression of mild cognitive impairment. Neuro-Degenerative Diseases. 6: 23-8. PMID 19066433 DOI: 10.1159/000170883 |
0.382 |
|
| 2009 |
Hirata-Fukae C, Li HF, Ma L, Hoe HS, Rebeck GW, Aisen PS, Matsuoka Y. Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo Neuroscience Letters. 450: 51-55. PMID 19022346 DOI: 10.1016/J.Neulet.2008.11.023 |
0.358 |
|
| 2009 |
Tractenberg RE, Aisen PS, Hancock GR, Rebeck GW. No cross-sectional influence of APOE epsilon4 dose on clinical tests in Alzheimer's disease. Neurobiology of Aging. 30: 1327-8. PMID 18083276 DOI: 10.1016/J.Neurobiolaging.2007.11.006 |
0.46 |
|
| 2009 |
Seneca N, Cai L, Liow JS, Zoghbi SS, Gladding R, Little JT, Aisen PS, Hong J, Pike VW, Innis RB. Low Retention of [S-methyl-11C]MeS-IMPY to β-amyloid Plaques in Patients with Alzheimers Disease Current Radiopharmaceuticals. 2: 129-136. DOI: 10.2174/1874471010902020129 |
0.411 |
|
| 2009 |
Donohue M, Gamst A, Aisen P. Designing Early (pre-dementia) Alzheimer's Disease Trials: Linear Mixed Models Versus Time To Conversion Alzheimers & Dementia. 5. DOI: 10.1016/J.Jalz.2009.07.084 |
0.497 |
|
| 2009 |
Shankle WR, Aisen P, Fleisher A, Petersen R, Ferris SH, Rafii M, Smith J. Reducing noise in the ADAS-COG wordlist task Alzheimers & Dementia. 5: 161. DOI: 10.1016/J.Jalz.2009.05.556 |
0.548 |
|
| 2009 |
Quinn JF, Raman R, Thomas RG, Ernstrom K, Yurko-Mauro K, Nelson EB, Shinto L, Nair AK, Aisen P. A clinical trial of docosahexanoic acid (DHA) for the treatment of Alzheimer's disease Alzheimers & Dementia. 5: 84. DOI: 10.1016/J.Jalz.2009.05.215 |
0.484 |
|
| 2009 |
Aisen PS, Schneider LS, Sano M. High-dose B vitamin supplements and alzheimer disease reply Jama - Journal of the American Medical Association. 301: 1021-1022. DOI: 10.1001/Jama.2009.213 |
0.349 |
|
| 2008 |
Aisen PS. Amyloid-based therapeutics: findings translated into novel treatments. Cns Spectrums. 13: 36-38. PMID 18955961 DOI: 10.1017/S109285290002705X |
0.339 |
|
| 2008 |
Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, Bottiglieri T, Jin S, Stokes KT, Thomas RG, Thal LJ. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. Jama. 300: 1774-83. PMID 18854539 DOI: 10.1001/Jama.300.15.1774 |
0.397 |
|
| 2008 |
Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Archives of Neurology. 65: 1031-8. PMID 18695053 DOI: 10.1001/Archneur.65.8.1031 |
0.454 |
|
| 2008 |
Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet (London, England). 372: 207-15. PMID 18640457 DOI: 10.1016/S0140-6736(08)61074-0 |
0.496 |
|
| 2008 |
Aisen PS. Leon Thal and the therapeutic age of Alzheimer's disease. Alzheimers & Dementia. 4. PMID 18631999 DOI: 10.1016/J.Jalz.2007.12.001 |
0.47 |
|
| 2008 |
Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, ... ... Aisen PS, et al. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 4: 156-63. PMID 18631960 DOI: 10.1016/J.Jalz.2008.03.005 |
0.485 |
|
| 2008 |
Aisen PS. Treatment for MCI: Is the evidence sufficient? Neurology. 70: 2020-2021. PMID 18505976 DOI: 10.1212/01.Wnl.0000313380.89894.54 |
0.485 |
|
| 2008 |
Hirata-Fukae C, Li HF, Hoe HS, Gray AJ, Minami SS, Hamada K, Niikura T, Hua F, Tsukagoshi-Nagai H, Horikoshi-Sakuraba Y, Mughal M, Rebeck GW, LaFerla FM, Mattson MP, Iwata N, ... ... Aisen PS, et al. Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Research. 1216: 92-103. PMID 18486110 DOI: 10.1016/J.Brainres.2008.03.079 |
0.422 |
|
| 2008 |
Hirata-Fukae C, Sidahmed EH, Gooskens TP, Aisen PS, Dewachter I, Devijver H, Van Leuven F, Matsuoka Y. Beta-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo. Neuroscience Letters. 435: 186-9. PMID 18343582 DOI: 10.1016/J.Neulet.2008.02.032 |
0.377 |
|
| 2008 |
Aisen PS. The inflammatory hypothesis of Alzheimer disease: dead or alive? Alzheimer Disease & Associated Disorders. 22: 4-5. PMID 18317241 DOI: 10.1097/Wad.0B013E318166Ca4C |
0.451 |
|
| 2008 |
Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, Lines CR, Norman BA, Potter WZ. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Current Alzheimer Research. 5: 73-82. PMID 18288935 DOI: 10.2174/156720508783884602 |
0.508 |
|
| 2008 |
Little JT, Walsh S, Aisen PS. An update on huperzine A as a treatment for Alzheimer's disease. Expert Opinion On Investigational Drugs. 17: 209-15. PMID 18230054 DOI: 10.1517/13543784.17.2.209 |
0.522 |
|
| 2008 |
Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS. A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. The Journal of Pharmacology and Experimental Therapeutics. 325: 146-53. PMID 18199809 DOI: 10.1124/Jpet.107.130526 |
0.453 |
|
| 2008 |
Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, Jack CR, Aisen PS, Thal LJ. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 70: 191-9. PMID 18195264 DOI: 10.1212/01.Wnl.0000287091.57376.65 |
0.489 |
|
| 2008 |
Aisen PS. An aspirin a day for Alzheimer's disease? Lancet Neurology. 7: 20-21. PMID 18068519 DOI: 10.1016/S1474-4422(07)70296-X |
0.457 |
|
| 2008 |
Aisen PS, Briand R, Saumier D, Laurin J, Duong A, Garceau D. Targeting amyloid with tramiprosate in patients with mild-to-moderate Alzheimer disease Progress in Neurotherapeutics and Neuropsychopharmacology. 3: 111-125. DOI: 10.1017/S1748232107000171 |
0.525 |
|
| 2008 |
Doody R, Seely L, Thomas R, Sano M, Aisen P. Statistical treatment of withdrawal in trials of anti-dementia drugs – Authors' reply The Lancet. 372: 1383. DOI: 10.1016/S0140-6736(08)61582-2 |
0.345 |
|
| 2008 |
Aisen PS. PL-05-02: The evolution of Alzheimer's disease clinical trial design Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.555 |
0.492 |
|
| 2008 |
Matsuoka Y, Jouroukhin Y, Gozes I, Aisen PS. O4-04-03: A neuronal microtubule-interacting agent, nap, reduces hyperphosphorylated Tau and insoluble Tau, and enhances cognitive function in a transgenic mouse model of Alzheimer's disease Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.529 |
0.431 |
|
| 2008 |
Sabbagh MN, Bell J, Agro A, Aisen P, Galasko D. P4-389: An oral antagonist of the receptor for advanced glycation end products (RAGE) is safe and well-tolerated in the treatment of Alzheimer's disease: Results from a phase II study Alzheimer's & Dementia. 4: T788-T788. DOI: 10.1016/J.Jalz.2008.05.2459 |
0.385 |
|
| 2008 |
Raman R, Emond J, Thomas RG, Petersen RC, Schneider LS, Aisen PS, Sano M. P4-387: Adding delayed recall to the Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog): Sensitivity in a clinical trial for Alzheimer's disease and mild cognitive impairment Alzheimer's & Dementia. 4: T787-T788. DOI: 10.1016/J.Jalz.2008.05.2457 |
0.555 |
|
| 2008 |
Quinn JF, Raman R, Thomas R, Ernstrom K, Yurko-Mauro K, Nelson E, Aisen PS. P4-343: Omega 3 fatty acids and Alzheimer's disease: Trial design and baseline study population characteristics in a clinical trial of docosahexanoic acid for Alzheimer's disease Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.2413 |
0.476 |
|
| 2008 |
Doody RS, Gavrilova S, Thomas R, Aisen P, Bachurin S, Seely L, Hung D. P4-337: Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.2407 |
0.46 |
|
| 2008 |
Cummings J, Doody R, Gavrilova S, Sano M, Aisen P, Seely L, Hung D. P4-334: Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.2404 |
0.454 |
|
| 2008 |
Petersen RC, Aisen P, Beckett L, Donohue M, Weng Q, Salmon D, Weiner M. P3-040: Alzheimer's disease neuroimaging initiative: Baseline characteristics Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.1603 |
0.49 |
|
| 2007 |
Aisen PS. Commentary on "The Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006."--an appraisal. Alzheimers & Dementia. 3: 446-448. PMID 19595967 DOI: 10.1016/J.Jalz.2007.09.002 |
0.468 |
|
| 2007 |
Tractenberg RE, Weiner MF, Aisen PS, Kaye JA, Fuh JL. A simple method to rule out dementia with temporal orientation. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 3: 28-32. PMID 19595914 DOI: 10.1016/J.Jalz.2006.10.005 |
0.395 |
|
| 2007 |
Takata K, Hirata-Fukae C, Becker AG, Chishiro S, Gray AJ, Nishitomi K, Franz AH, Sakaguchi G, Kato A, Mattson MP, Laferla FM, Aisen PS, Kitamura Y, Matsuoka Y. Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. The European Journal of Neuroscience. 26: 2458-68. PMID 17970733 DOI: 10.1111/J.1460-9568.2007.05852.X |
0.338 |
|
| 2007 |
Aisen PS, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D. Alzhemed: a potential treatment for Alzheimer's disease. Current Alzheimer Research. 4: 473-8. PMID 17908052 DOI: 10.2174/156720507781788882 |
0.523 |
|
| 2007 |
Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. Journal of Molecular Neuroscience : Mn. 31: 165-70. PMID 17478890 DOI: 10.1385/Jmn/31:02:165 |
0.454 |
|
| 2007 |
Gray AJ, Sakaguchi G, Shiratori C, Becker AG, LaFrancois J, Aisen PS, Duff K, Matsuoka Y. Antibody against C-terminal Abeta selectively elevates plasma Abeta. Neuroreport. 18: 293-6. PMID 17314674 DOI: 10.1097/Wnr.0B013E3280148E76 |
0.312 |
|
| 2007 |
Little JT, Walsh S, Aisen P. AbstractPosterP-198: Huperzine A as a treatment for Alzheimer’s disease Alzheimers & Dementia. 3. DOI: 10.1016/J.Jalz.2007.04.161 |
0.368 |
|
| 2006 |
Tractenberg RE, Aisen PS, Weiner MF, Cummings JL, Hancock GR. Independent contributions of neural and "higher-order" deficits to symptoms in Alzheimer's disease: a latent variable modeling approach. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2: 303-13. PMID 19595904 DOI: 10.1016/J.Jalz.2006.08.001 |
0.345 |
|
| 2006 |
Aisen PS. Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials". Alzheimers & Dementia. 2: 272-274. PMID 19595898 DOI: 10.1016/J.Jalz.2006.08.004 |
0.535 |
|
| 2006 |
Aisen PS. Development of a disease-modifying treatment for Alzheimer's disease: Alzhemed. Alzheimers & Dementia. 2: 153-154. PMID 19595875 DOI: 10.1016/J.Jalz.2006.03.009 |
0.505 |
|
| 2006 |
Walsh SP, Raman R, Jones KB, Aisen PS. ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI). Alzheimer Disease and Associated Disorders. 20: S170-8. PMID 17135810 DOI: 10.1097/01.Wad.0000213879.55547.57 |
0.497 |
|
| 2006 |
Ferris SH, Aisen PS, Cummings J, Galasko D, Salmon DP, Schneider L, Sano M, Whitehouse PJ, Edland S, Thal LJ. ADCS Prevention Instrument Project: overview and initial results. Alzheimer Disease and Associated Disorders. 20: S109-23. PMID 17135805 DOI: 10.1097/01.Wad.0000213870.40300.21 |
0.461 |
|
| 2006 |
Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, ... ... Aisen PS, et al. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. Journal of Neurochemistry. 99: 1555-63. PMID 17083447 DOI: 10.1111/J.1471-4159.2006.04178.X |
0.353 |
|
| 2006 |
Aisen PS, Saumier D, Briand R, Laurin J, Gervais F, Tremblay P, Garceau D. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 67: 1757-63. PMID 17082468 DOI: 10.1212/01.Wnl.0000244346.08950.64 |
0.486 |
|
| 2006 |
Matsuoka Y, Gozes I, Aisen PS. NAP ameliorates Alzheimer’s pathology in ad model mouse Neuropeptides. 40: 432-433. DOI: 10.1016/J.Npep.2006.09.022 |
0.413 |
|
| 2006 |
Papp KV, Rentz DM, Maruff P, Sun C, Raman R, Donohue MC, Schembri A, Stark CE, Yassa MA, Holdridge KC, Wessels AM, Yaari R, Aisen PS, Sperling RA. P4-341: THE COMPUTERIZED COGNITIVE COMPOSITE (C3) AND AMYLOID STATUS AMONG NORMAL OLDER ADULTS Alzheimer's & Dementia. 14: P1597-P1598. DOI: 10.1016/J.Jalz.2018.07.164 |
0.468 |
|
| 2006 |
Johnson KA, Schultz AP, Raman R, Donohue MC, Sun C, Jacobs HI, Marek K, Seibyl J, Mintun MA, Shcherbinin S, Pontecorvo MJ, Mormino BC, Rowe CC, van Dyck CH, Salloway S, ... ... Aisen PS, et al. P4-321: TAU PET IN A4: PRELIMINARY REPORT Alzheimer's & Dementia. 14: P1583-P1584. DOI: 10.1016/J.Jalz.2018.07.144 |
0.431 |
|
| 2006 |
Ravindranath PA, Kavatkar M, Rafii MS, Aisen PS, Jimenez-Maggiora G. P1-345: CLASSIFICATION OF EMOTIONAL RESPONSES IN VIDEO AND AUDIO RECORDINGS USING A CONVOLUTIONAL NEURAL NETWORK Alzheimer's & Dementia. 14: P426-P426. DOI: 10.1016/J.Jalz.2018.06.352 |
0.553 |
|
| 2006 |
Donohue MC, Raman R, Sun C, Langford O, Johnson KA, Aisen PS, Sperling RA. O1-02-05: PREDICTING AMYLOID BURDEN IN SCREENING FOR PRECLINICAL AD PREVENTION TRIALS Alzheimer's & Dementia. 14: P217-P218. DOI: 10.1016/J.Jalz.2018.06.2340 |
0.545 |
|
| 2006 |
Ravindranath PA, Raman R, Chow TW, Rafii MS, Aisen PS, Jimenez-Maggiora G. P3-014: DEEP LEARNING IN AUTOMATED CLASSIFICATION OF ADVERSE EVENTS IN CLINICAL STUDIES OF ALZHEIMER'S DISEASE Alzheimer's & Dementia. 14: P1067-P1068. DOI: 10.1016/j.jalz.2018.06.1369 |
0.649 |
|
| 2006 |
Ravindranath PA, Hong P, Rafii MS, Aisen PS, Jimenez-Maggiora G. P2-571: A STEP FORWARD IN INTEGRATING HEALTHCARE AND VOICE-ENABLED TECHNOLOGY: CONCEPT DEMONSTRATION WITH DEPLOYMENT OF AUTOMATIC MEDICAL CODING MODEL AS AN AMAZON “ALEXA” SKILL Alzheimer's & Dementia. 14: P955-P955. DOI: 10.1016/J.Jalz.2018.06.1266 |
0.558 |
|
| 2006 |
Ravindranath PA, Raman R, Chow TW, Rafii MS, Aisen PS, Jimenez-Maggiora G. TD-P-016: DEEP LEARNING IN AUTOMATED CLASSIFICATION OF ADVERSE EVENTS IN CLINICAL STUDIES OF ALZHEIMER'S DISEASE Alzheimer's & Dementia. 14: P193-P193. DOI: 10.1016/J.Jalz.2017.06.1871 |
0.68 |
|
| 2006 |
Walsh S, Thal L, Aisen PS. P2-400: The development of huperzine A as a treatment for Alzheimer’s disease Alzheimers & Dementia. 2. DOI: 10.1016/J.Jalz.2006.05.1239 |
0.35 |
|
| 2005 |
Aisen PS. Can rofecoxib delay a diagnosis of Alzheimer's disease in patients with mild cognitive impairment? Nature Reviews Neurology. 1: 20-21. PMID 16932488 DOI: 10.1038/Ncpneuro0039 |
0.506 |
|
| 2005 |
Gozes I, Morimoto BH, Tiong J, Fox A, Sutherland K, Dangoor D, Holser-Cochav M, Vered K, Newton P, Aisen PS, Matsuoka Y, van Dyck CH, Thal L. NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP). Cns Drug Reviews. 11: 353-68. PMID 16614735 DOI: 10.1111/J.1527-3458.2005.Tb00053.X |
0.349 |
|
| 2005 |
Aisen PS. The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. Cns Drugs. 19: 989-996. PMID 16332141 DOI: 10.2165/00023210-200519120-00002 |
0.449 |
|
| 2005 |
Tractenberg RE, Aisen PS, Chuang YL. One-trial 10-item free-recall performance in Taiwanese elderly and near-elderly: A potential screen for cognitive decline. American Journal of Alzheimer's Disease and Other Dementias. 20: 239-47. PMID 16136848 DOI: 10.1177/153331750502000410 |
0.348 |
|
| 2005 |
Aisen PS. Pharmacologic treatment options in Alzheimer's disease: optimizing disease management. Journal of the American Academy of Nurse Practitioners. 5-7. PMID 16033023 |
0.329 |
|
| 2005 |
Matsuoka Y, Shao L, Debnath M, Lafrancois J, Becker A, Gray A, Aisen P, Mathis C, Klunk W, Duff K. An Abeta sequestration approach using non-antibody Abeta binding agents. Current Alzheimer Research. 2: 265-8. PMID 15974928 DOI: 10.2174/1567205053585774 |
0.33 |
|
| 2005 |
Tractenberg RE, Weinstein M, Weiner MF, Aisen PS, Fuh JL, Goldman N, Chuang YL. Benchmarking a test of temporal orientation with data from american and taiwanese persons with Alzheimer's disease and american normal elderly. Neuroepidemiology. 24: 110-6. PMID 15492486 DOI: 10.1159/000081610 |
0.394 |
|
| 2005 |
Sano M, Aisen PS, Dalton AJ, Andrews HF, Tsai W. Assessment of Aging Individuals with Down Syndrome in Clinical Trials: Results of Baseline Measures Journal of Policy and Practice in Intellectual Disabilities. 2: 126-138. DOI: 10.1111/J.1741-1130.2005.00021.X |
0.404 |
|
| 2005 |
Aisen PS, Dalton AJ, Sano M, Lott IT, Andrews HF, Tsai W-. Design and Implementation of a Multicenter Trial of Vitamin E in Aging Individuals with Down Syndrome Journal of Policy and Practice in Intellectual Disabilities. 2: 86-93. DOI: 10.1111/J.1741-1130.2005.00020.X |
0.438 |
|
| 2005 |
Sano M, Aisen P, Andrews H, Dalton A. Developing outcome measures for therapeutic trials for dementia in aging individuals with Down Syndrome Alzheimers & Dementia. 1. DOI: 10.1016/J.Jalz.2005.06.290 |
0.336 |
|
| 2005 |
Aisen PS. Clinical trials of anti-amyloid agents Alzheimers & Dementia. 1. DOI: 10.1016/J.Jalz.2005.06.040 |
0.361 |
|
| 2005 |
Tremblay P, Aisen P, Garceau D. Functional GAG mimetics as an approach for the treatment of amyloid diseases Alzheimers & Dementia. 1. DOI: 10.1016/J.Jalz.2005.06.033 |
0.397 |
|
| 2005 |
Aisen PS. Emerging treatment strategies for alzheimer’s disease Current Psychosis & Therapeutics Reports. 3: 15-19. DOI: 10.1007/Bf02629404 |
0.477 |
|
| 2004 |
Walsh S, Aisen PS. Inflammatory processes and Alzheimer’s disease Expert Review of Neurotherapeutics. 4: 793-798. PMID 15853506 DOI: 10.1586/14737175.4.5.793 |
0.363 |
|
| 2004 |
Horikoshi Y, Sakaguchi G, Becker AG, Gray AJ, Duff K, Aisen PS, Yamaguchi H, Maeda M, Kinoshita N, Matsuoka Y. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochemical and Biophysical Research Communications. 319: 733-7. PMID 15184044 DOI: 10.1016/J.Bbrc.2004.05.051 |
0.344 |
|
| 2004 |
Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Archives of Neurology. 61: 59-66. PMID 14732621 DOI: 10.1001/Archneur.61.1.59 |
0.49 |
|
| 2004 |
Karlawish J, Lu M, Logsdon R, Whitehouse P, Aisen P. P2-321 How much do 12 month changes in cognition and function influence changes in mild to moderate AD patients and caregivers ratings of patient quality of life? Neurobiology of Aging. 25. DOI: 10.1016/S0197-4580(04)81065-0 |
0.35 |
|
| 2003 |
van Gool WA, Aisen PS, Eikelenboom P. Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? Journal of Neurology. 250: 788-92. PMID 12883918 DOI: 10.1007/S00415-003-1146-5 |
0.451 |
|
| 2003 |
Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Jama. 289: 2819-26. PMID 12783912 DOI: 10.1001/Jama.289.21.2819 |
0.626 |
|
| 2003 |
Mehta PD, Patrick BA, Pirttila T, Coyle PK, Aisen PS. Detection of apolipoprotein E phenotype in unconcentrated cerebrospinal fluid Journal of Clinical Laboratory Analysis. 17: 18-21. PMID 12526018 DOI: 10.1002/Jcla.10063 |
0.345 |
|
| 2003 |
Aisen PS, Berg JD, Craft S, Peskind ER, Sano M, Teri L, Mulnard RA, Thomas RG, Thal LJ. Steroid-induced elevation of glucose in Alzheimer's disease: relationship to gender, apolipoprotein E genotype and cognition. Psychoneuroendocrinology. 28: 113-20. PMID 12445840 DOI: 10.1016/S0306-4530(02)00015-X |
0.359 |
|
| 2003 |
Aisen PS, Egelko S, Andrews H, Diaz-Arrastia R, Weiner M, DeCarli C, Jagust W, Miller JW, Green R, Bell K, Sano M. A Pilot Study of Vitamins to Lower Plasma Homocysteine Levels in Alzheimer Disease The American Journal of Geriatric Psychiatry. 11: 246-249. DOI: 10.1097/00019442-200303000-00016 |
0.378 |
|
| 2003 |
Aisen PS, Schafer KA, Grundman M, Knopman DS, Tabet N. Neither rofecoxib nor naproxen slows cognitive decline in people with mild-to-moderate Alzheimer's disease Evidence-Based Healthcare. 7: 200-201. DOI: 10.1016/J.Ehbc.2003.08.001 |
0.498 |
|
| 2002 |
Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurology. 1: 279-284. PMID 12849425 DOI: 10.1016/S1474-4422(02)00133-3 |
0.431 |
|
| 2002 |
Aisen PS. Anti-inflammatory agents in Alzheimer's disease. Current Neurology and Neuroscience Reports. 2: 405-409. PMID 12169220 DOI: 10.1007/S11910-002-0066-6 |
0.359 |
|
| 2002 |
Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. Journal of Pain and Symptom Management. 23. PMID 11992749 DOI: 10.1016/S0885-3924(02)00374-3 |
0.539 |
|
| 2002 |
Xiang Z, Ho L, Valdellon J, Borchelt D, Kelley K, Spielman L, Aisen PS, Pasinetti GM. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiology of Aging. 23: 327-34. PMID 11959394 DOI: 10.1016/S0197-4580(01)00282-2 |
0.393 |
|
| 2002 |
Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology. 58: 1050-4. PMID 11940691 DOI: 10.1212/Wnl.58.7.1050 |
0.458 |
|
| 2002 |
Spielman L, Winger D, Ho L, Aisen PS, Shohami E, Pasinetti GM. Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2. Acta Neuropathologica. 103: 157-62. PMID 11810182 DOI: 10.1007/S004010100447 |
0.332 |
|
| 2002 |
Aisen PS. Development of antiinflammatory therapy for Alzheimer's disease Drug Development Research. 56: 421-427. DOI: 10.1002/Ddr.10094 |
0.51 |
|
| 2001 |
Aisen PS, Marin DB, Brickman AM, Santoro J, Fusco M. Pilot tolerability studies of hydroxychloroquine and colchicine in Alzheimer disease Alzheimer Disease and Associated Disorders. 15: 96-101. PMID 11403336 DOI: 10.1097/00002093-200104000-00009 |
0.456 |
|
| 2001 |
Ho L, Purohit D, Haroutunian V, Luterman JD, Willis F, Naslund J, Buxbaum JD, Mohs RC, Aisen PS, Pasinetti GM. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Archives of Neurology. 58: 487-92. PMID 11255454 DOI: 10.1001/Archneur.58.3.487 |
0.465 |
|
| 2001 |
Ho L, Guo Y, Spielman L, Petrescu O, Haroutunian V, Purohit D, Czernik A, Yemul S, Aisen PS, Mohs R, Pasinetti GM. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique. Neuroscience Letters. 298: 191-4. PMID 11165439 DOI: 10.1016/S0304-3940(00)01753-5 |
0.42 |
|
| 2000 |
Aisen PS. Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. Acta Neurologica Scandinavica. 102: 85-89. PMID 11261810 DOI: 10.1034/J.1600-0404.2000.00312.X |
0.5 |
|
| 2000 |
Hull M, Pasinetti GM, Aisen PS. Elevated plasma neopterin levels in Alzheimer disease. Alzheimer Disease and Associated Disorders. 14: 228-30. PMID 11186601 DOI: 10.1097/00002093-200010000-00007 |
0.41 |
|
| 2000 |
Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, Mohs R, Pasinetti GM. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Archives of Neurology. 57: 1153-60. PMID 10927795 DOI: 10.1001/Archneur.57.8.1153 |
0.425 |
|
| 2000 |
Aisen PS. Anti-inflammatory therapy for Alzheimer's disease. Neurobiology of Aging. 21: 447-448. PMID 10858592 DOI: 10.1016/S0197-4580(00)00140-8 |
0.405 |
|
| 2000 |
Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 54: 588-93. PMID 10680787 DOI: 10.1212/WNL.54.3.588 |
0.538 |
|
| 2000 |
Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Archives of Neurology. 57: 100-5. PMID 10634455 DOI: 10.1001/Archneur.57.1.100 |
0.425 |
|
| 1999 |
Mehta PD, Patrick BA, Dalton AJ, Aisen PS, Emmerling ME, Sersen EA, Wisniewski HM. Increased levels of tau-like protein in patients with Down syndrome. Neuroscience Letters. 275: 159-62. PMID 10580699 DOI: 10.1016/S0304-3940(99)00754-5 |
0.339 |
|
| 1999 |
Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. Journal of Neuroscience Research. 57: 295-303. PMID 10412020 DOI: 10.1002/(Sici)1097-4547(19990801)57:3<295::Aid-Jnr1>3.0.Co;2-0 |
0.42 |
|
| 1998 |
Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 87: 319-24. PMID 9740394 DOI: 10.1016/S0306-4522(98)00218-8 |
0.443 |
|
| 1998 |
Gabriel SM, Marin DB, Aisen PS, Lantz M, Altstiel LD, Davis KL, Mohs RC. Association of elevated alpha 1-antichymotrypsin with cognitive impairment in a prospective study of the very old. The American Journal of Psychiatry. 155: 698-700. PMID 9585727 DOI: 10.1176/Ajp.155.5.698 |
0.482 |
|
| 1998 |
Aisen PS, Pasinetti GM. Glucocorticoids in Alzheimer's disease. The story so far. Drugs & Aging. 12: 1-6. PMID 9467682 DOI: 10.2165/00002512-199812010-00001 |
0.336 |
|
| 1997 |
Aisen PS, Davis KL. The search for disease-modifying treatment for Alzheimer's disease. Neurology. 48: S35-41. PMID 9153159 DOI: 10.1212/Wnl.48.5_Suppl_6.35S |
0.571 |
|
| 1997 |
Lawlor BA, Aisen PS, Green C, Fine E, Schmeidler J. Selegiline in the treatment of behavioural disturbance in Alzheimer's disease. International Journal of Geriatric Psychiatry. 12: 319-322. PMID 9152715 DOI: 10.1002/(Sici)1099-1166(199703)12:3<319::Aid-Gps488>3.0.Co;2-Q |
0.476 |
|
| 1997 |
Aisen PS. Inflammation and Alzheimer’s Disease: Mechanisms and Therapeutic Strategies Gerontology. 43: 143-149. PMID 8996836 DOI: 10.1159/000213842 |
0.324 |
|
| 1996 |
Aisen PS. Inflammation and Alzheimer disease. Molecular and Chemical Neuropathology. 28: 83-88. PMID 8871945 DOI: 10.1007/Bf02815208 |
0.495 |
|
| 1996 |
Aisen PS, Marin D, Altstiel L, Goodwin C, Baruch B, Jacobson R, Ryan T, Davis KL. A pilot study of prednisone in Alzheimer's disease. Dementia (Basel, Switzerland). 7: 201-6. PMID 8835883 DOI: 10.1159/000106879 |
0.584 |
|
| 1996 |
Aisen PS, Marin D, Davis KL. Anti-inflammatory drug studies in Alzheimer's disease Biological Psychiatry. 39: 563. DOI: 10.1016/0006-3223(96)84163-1 |
0.508 |
|
| 1995 |
Aisen PS, Davis KL. Drs. Aisen and Davis Reply American Journal of Psychiatry. 152: 1242-1242. DOI: 10.1176/Ajp.152.8.1242 |
0.351 |
|
| 1995 |
Schafer K, Thal L, Bochenek J, Sano M, Grundman M, Woodbury P, Klauber M, Aisen P. P44 Implementation of multicenter clinical trials: The Alzheimer's Disease Cooperative Study protocol implementation manual Controlled Clinical Trials. 16: 97S. DOI: 10.1016/0197-2456(95)90524-9 |
0.473 |
|
| Show low-probability matches. |